Hereditary Spastic Paraplegia

Mendelian MONDO:0019064 Pathograph 10 Show in embeddings browser

Hereditary spastic paraplegia (HSP) is a clinically and genetically heterogeneous group of inherited neurodegenerative disorders unified by length-dependent distal axonal degeneration of the corticospinal-tract upper motor neurons, maximal at the distal ends of the longest central nervous system axons in the thoracic spinal cord, with accompanying degeneration of the fasciculus gracilis (dorsal column) sensory fibers. More than 80 spastic paraplegia (SPG) genetic loci have been described, encoding proteins with diverse functions including axonal transport (SPAST/spastin microtubule severing), endoplasmic reticulum morphogenesis (ATL1/atlastin-1, SPAST/spastin, REEP1), mitochondrial quality control and oxidative phosphorylation (SPG7/paraplegin), and lipid/membrane and lysosomal-endosomal trafficking (SPG11/spatacsin). Despite this molecular diversity, the converging pathology is relatively selective corticospinal-tract axonopathy producing the shared clinical syndrome of progressive lower-limb spasticity and weakness with hyperreflexia and extensor plantar responses. HSP is divided clinically into "pure" (uncomplicated) forms, in which spasticity and weakness of the legs with subtle dorsal-column impairment and urinary urgency are the only features, and "complex" (complicated) forms, in which spastic paraplegia is accompanied by additional neurologic or systemic features such as thin corpus callosum, cognitive decline, peripheral neuropathy, ataxia, or distal amyotrophy.

Ask OpenScientist

Ask a research question about Hereditary Spastic Paraplegia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

2
Inheritance
5
Pathophys.
13
Phenotypes
10
Pathograph
4
Genes
4
Medical Actions
6
Subtypes
4
References
1
Deep Research
👪

Inheritance

2
Autosomal Dominant HP:0000006
Autosomal dominant HSP includes the most common forms SPG4 (SPAST) and SPG3A (ATL1). Penetrance is age-dependent and may be high (80-90% in SPG4) or as low as 70%.
Autosomal dominant inheritance
Show evidence (2 references)
PMID:20301339 SUPPORT Human Clinical
"SPAST-HSP is inherited in an autosomal dominant manner with age-related, nearly complete penetrance"
Establishes autosomal dominant inheritance with age-related penetrance for the most common HSP form.
PMID:23897027 SUPPORT Human Clinical
"Genetic penetrance in autosomal dominant HSP is age-dependent, may be high (80-90% in SPG4 HSP) or as low as 70%"
Quantifies the age-dependent penetrance of autosomal dominant HSP.
Autosomal Recessive HP:0000007
Autosomal recessive HSP includes SPG7 (paraplegin) and SPG11 (spatacsin), which usually present as complex HSP and require biallelic pathogenic variants.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:20301389 SUPPORT Human Clinical
"SPG11 is inherited in an autosomal recessive manner."
Establishes autosomal recessive inheritance for the common complex HSP form SPG11.
◆

Subtypes

6
Pure (Uncomplicated) Hereditary Spastic Paraplegia
Clinical classification in which lower-extremity spasticity and weakness, with subtle lower-extremity dorsal-column (vibration sense) impairment and urinary urgency, are the predominant or only manifestations. Affected individuals typically have normal life expectancy and do not develop significant upper-extremity, bulbar, or cognitive involvement. SPG4 (SPAST) is the prototypical and single most common cause of pure autosomal dominant HSP.
Show evidence (1 reference)
PMID:23897027 SUPPORT Human Clinical
"“uncomplicated” (characterized by lower extremity spasticity and weakness and subtle lower extremity dorsal column impairment)"
Defines the pure/uncomplicated HSP clinical category by its restricted feature set.
Complex (Complicated) Hereditary Spastic Paraplegia
Clinical classification in which spastic paraplegia is associated with additional neurologic or systemic abnormalities, including dementia or cognitive impairment, ataxia, intellectual disability, peripheral neuropathy, distal wasting, loss of vision, epilepsy, ichthyosis, or thin corpus callosum on neuroimaging. SPG11 (spatacsin) is a common autosomal recessive cause of complex HSP. Correlation between the clinical pure-versus-complex split and the underlying genetic type is imperfect, and many genetic types can present as either form.
Show evidence (2 references)
PMID:23897027 SUPPORT Human Clinical
"“complicated” (in which spastic paraplegia is associated with additional neurologic or systemic abnormalities including dementia, ataxia, mental retardation, neuropathy, distal wasting, loss of vision, epilepsy, or icthyosis"
Defines the complex/complicated HSP clinical category by the spectrum of additional features.
PMID:23897027 SUPPORT Human Clinical
"There is imperfect correlation between clinical classification (“uncomplicated” versus “complicated”) and genetic types of HSP."
Notes that the pure-versus-complex clinical split does not map cleanly onto genetic subtype.
Spastic Paraplegia 4 (SPAST-HSP)
SPAST hgnc:11233 Autosomal dominant inheritance
Autosomal dominant HSP caused by heterozygous pathogenic variants in SPAST, encoding the microtubule-severing AAA ATPase spastin. SPG4 is the single most common form of autosomal dominant HSP and is the prototype of pure HSP, though dementia, ataxia, thin corpus callosum, and muscle wasting have been reported. Onset is insidious, mostly in young adulthood, with considerable intrafamilial variation.
Show evidence (1 reference)
PMID:20301339 SUPPORT Human Clinical
"Spastic paraplegia 4 (SPG4; also known as SPAST-HSP) is characterized by insidiously progressive bilateral lower-limb gait spasticity."
GeneReviews establishes SPG4/SPAST-HSP as a distinct autosomal dominant HSP subtype.
Spastic Paraplegia 3A (ATL1-HSP)
ATL1 hgnc:11231 Autosomal dominant inheritance
Autosomal dominant HSP caused by heterozygous pathogenic variants in ATL1, encoding atlastin-1, a dynamin-like GTPase that mediates homotypic fusion of endoplasmic reticulum tubules. SPG3A is the most common cause of early childhood-onset autosomal dominant HSP, with average age of onset around four years and a relatively slow, often non-progressive course. Usually a pure HSP, but complicated forms with axonal motor neuropathy and distal amyotrophy (Silver syndrome phenotype) occur.
Show evidence (2 references)
PMID:20862796 SUPPORT Human Clinical
"Spastic paraplegia 3A (SPG3A; also known as ATL1-HSP) is characterized by progressive bilateral and mostly symmetric spasticity and weakness of the legs."
GeneReviews establishes SPG3A/ATL1-HSP as a distinct autosomal dominant HSP subtype.
PMID:20862796 SUPPORT Human Clinical
"The average age of onset is four years. More than 80% of reported individuals manifest spastic gait before the end of the first decade of life."
Documents the characteristic early-childhood onset distinguishing SPG3A.
Spastic Paraplegia 7 (SPG7/paraplegin)
SPG7 hgnc:11237 Autosomal recessive inheritance
Most commonly autosomal recessive HSP caused by biallelic pathogenic variants in SPG7, encoding paraplegin, a nuclear-encoded mitochondrial metalloprotease (m-AAA protease) of the inner mitochondrial membrane. SPG7-HSP frequently presents as complex HSP with cerebellar ataxia, ophthalmoplegia/ptosis, optic atrophy, and mitochondrial cytopathy on muscle biopsy, reflecting oxidative-phosphorylation impairment, but pure forms also occur. Some heterozygous SPG7 variants have been associated with dominantly transmitted disease.
Show evidence (2 references)
PMID:9635427 SUPPORT Human Clinical
"We found that patients from a chromosome 16q24.3-linked HSP family are homozygous for a 9.5 kb deletion involving a gene encoding a novel protein, named Paraplegin."
Original identification of recessive SPG7 caused by biallelic paraplegin mutations.
PMID:23897027 SUPPORT Human Clinical
"SPG7 HSP was originally described as an autosomal recessive disorder due to homozygous or compound heterozygous SPG7/paraplegin gene mutations."
Confirms SPG7 as predominantly autosomal recessive HSP.
Spastic Paraplegia 11 (SPG11/spatacsin)
SPG11 hgnc:11226 Autosomal recessive inheritance
Autosomal recessive complex HSP caused by biallelic pathogenic variants in SPG11, encoding spatacsin. SPG11 is one of the most common forms of autosomal recessive HSP and is characteristically associated with thinning of the corpus callosum, mild intellectual disability or progressive cognitive decline, peripheral neuropathy, and pseudobulbar involvement. Onset is usually in infancy or adolescence, and most affected individuals become wheelchair-bound one or two decades after onset.
Show evidence (1 reference)
PMID:20301389 SUPPORT Human Clinical
"Spastic paraplegia 11 (SPG11) is characterized by progressive spasticity and weakness of the lower limbs frequently associated with the following: mild intellectual disability with learning difficulties in childhood and/or progressive cognitive decline; peripheral neuropathy; pseudobulbar..."
GeneReviews establishes SPG11 as a distinct complex autosomal recessive HSP subtype.
⚙

Pathophysiology

5
Length-Dependent Corticospinal-Tract Axonal Degeneration
The unifying pathology of HSP is degeneration of the lateral corticospinal tract axons, maximal at their distal ends in the thoracic spinal cord, with accompanying degeneration of the fasciculus gracilis (dorsal column) sensory fibers maximal in the cervico-medullary region. This pattern reflects a selective vulnerability of the longest motor and sensory axons of the central nervous system, a length-dependent distal axonopathy of the upper motor neuron. The diverse molecular causes of HSP converge on this relatively uniform corticospinal-tract degeneration, producing the shared clinical syndrome of progressive lower-limb spasticity and weakness.
Upper motor neuron (corticospinal tract) CL:0008048 Betz upper motor neuron CL:4023052
Neuron projection (axon) maintenance failure GO:1990535 ↓ DECREASED
Lateral corticospinal tract UBERON:0002589 Corticospinal tract UBERON:0002707
Downstream
Progressive Lower-Limb Spasticity and Weakness
Show evidence (3 references)
PMID:23897027 SUPPORT Human Clinical
"Postmortem studies consistently identify degeneration of corticospinal tract axons (maximal in the thoracic spinal cord) and degeneration of fasciculus gracilis fibers (maximal in the cervico-medullary region)."
Establishes the consistent corticospinal-tract and dorsal-column degeneration that defines HSP neuropathology.
PMID:23897027 SUPPORT Human Clinical
"HSP syndromes thus appear to involve motor-sensory axon degeneration affecting predominantly (but not exclusively) the distal ends of long central nervous system (CNS) axons."
Supports the length-dependent distal axonopathy concept central to HSP pathogenesis.
PMID:33439395 SUPPORT Human Clinical
"The most common neuropathological sign is the axonal degeneration involving the lateral corticospinal tracts in both the cervical and thoracic spinal cord."
Independent review confirms lateral corticospinal-tract axonal degeneration as the dominant neuropathology.
Spastin Microtubule-Severing Defect (SPG4)
Spastin, encoded by SPAST (SPG4), is a microtubule-severing AAA ATPase that assembles into a hexameric ring and remodels neuronal microtubule arrays by pulling the C-terminal tail of tubulin through its central pore to generate a mechanical force that destabilizes the microtubule lattice. Pathogenic SPAST variants impair this severing activity, disrupting the dynamic microtubule cytoskeleton required for axonal transport and organelle distribution in long corticospinal-tract axons. Spastin loss-of-function also disrupts cytoarchitectural integrity and organellar stability (mitochondrial and ER) in corticospinal motor neurons, contributing to selective UMN vulnerability.
Upper motor neuron (corticospinal tract) CL:0008048
Microtubule severing GO:0051013 ↓ DECREASED Axonal transport GO:0098930 ↓ DECREASED Mitochondrion organization GO:0007005 ↓ DECREASED Endoplasmic reticulum organization GO:0007029 ↓ DECREASED
Downstream
Length-Dependent Corticospinal-Tract Axonal Degeneration
Show evidence (4 references)
PMID:18202664 SUPPORT In Vitro
"Spastin, the most common locus for mutations in hereditary spastic paraplegias, and katanin are related microtubule-severing AAA ATPases"
Identifies spastin as a microtubule-severing AAA ATPase and the most common HSP locus.
PMID:18202664 SUPPORT In Vitro
"our data support a model in which spastin pulls the C terminus of tubulin through its central pore, generating a mechanical force that destabilizes tubulin-tubulin interactions within the microtubule lattice."
Defines the molecular mechanism of spastin-mediated microtubule severing disrupted in SPG4.
PMID:42320547 SUPPORT Model Organism
"limitations with cytoarchitectural integrity and stability of key organelles contribute to their neuronal vulnerability"
Proteomic analysis of SPASTC448Y mice reveals that spastin loss-of-function causes early cytoarchitectural defects and organellar instability contributing to corticospinal neuron vulnerability.
+ 1 more reference
Atlastin-1 ER Tubular Network Defect (SPG3A)
Atlastin-1, encoded by ATL1 (SPG3A), is a dynamin-like, integral-membrane GTPase that mediates homotypic fusion of endoplasmic reticulum tubules and is required for proper formation of the interconnected tubular ER network. ATL1 pathogenic variants impair ER-tubule fusion and network formation; because spastin, atlastin, REEP1, and reticulon-2 interact in shaping the tubular ER, ER-shaping defects are proposed as a shared neuropathogenic mechanism converging on corticospinal-tract axon degeneration.
Upper motor neuron (corticospinal tract) CL:0008048
Endoplasmic reticulum membrane fusion GO:0016320 ↓ DECREASED Endoplasmic reticulum tubular network organization GO:0071786 ↓ DECREASED
Endoplasmic reticulum tubular network GO:0071782
Downstream
Length-Dependent Corticospinal-Tract Axonal Degeneration
Show evidence (2 references)
PMID:19665976 SUPPORT In Vitro
"we show that mammalian atlastins, which are dynamin-like, integral membrane GTPases, interact with the tubule-shaping proteins. The atlastins localize to the tubular ER and are required for proper network formation in vivo and in vitro."
Establishes atlastin's role in forming the tubular ER network, disrupted in SPG3A.
PMID:19665976 SUPPORT In Vitro
"Since atlastin-1 mutations cause a common form of hereditary spastic paraplegia, we suggest ER-shaping defects as a neuropathogenic mechanism."
Directly links atlastin-1 mutations and HSP to ER-shaping defects as the proposed mechanism.
Paraplegin Mitochondrial Quality-Control and OXPHOS Failure (SPG7)
Paraplegin, encoded by SPG7, is a nuclear-encoded mitochondrial metalloprotease (m-AAA protease) embedded in the inner mitochondrial membrane, where it maintains mitochondrial protein quality by degrading damaged or unassembled respiratory-chain subunits. Loss of paraplegin function impairs oxidative phosphorylation; SPG7 patient cells show fragmented mitochondria, reduced mitochondrial mass and membrane potential, impaired oxidative phosphorylation with reduced ATP, and increased mitochondrial oxidative stress, providing a bioenergetic mechanism for corticospinal-tract neurodegeneration.
Upper motor neuron (corticospinal tract) CL:0008048
Mitochondrial protein quality control GO:0141164 ↓ DECREASED Oxidative phosphorylation GO:0006119 ↓ DECREASED
Downstream
Length-Dependent Corticospinal-Tract Axonal Degeneration
Show evidence (3 references)
PMID:9635427 SUPPORT Human Clinical
"Analysis of muscle biopsies from two patients carrying Paraplegin mutations showed typical signs of mitochondrial OXPHOS defects, thus suggesting a mechanism for neurodegeneration in HSP-type disorders."
Links paraplegin mutations to oxidative-phosphorylation defects as the neurodegenerative mechanism in SPG7.
PMID:32973427 SUPPORT In Vitro
"SPG7 patient cells had increased paraplegin expression, fragmented mitochondria with low interconnectivity, reduced mitochondrial mass, decreased mitochondrial membrane potential, reduced oxidative phosphorylation, reduced ATP content, increased mitochondrial oxidative stress, and reduced..."
Patient-derived SPG7 cells show the mitochondrial dysfunction phenotype underlying neurodegeneration.
PMID:32973427 SUPPORT In Vitro
"Mitochondrial dysfunction was specific to SPG7 patient cells and not present in SPAST patient cells, which displayed mitochondrial functions similar to control cells."
Demonstrates genotype-specific mitochondrial pathology, distinguishing the SPG7 mechanism from SPG4/SPAST.
Progressive Lower-Limb Spasticity and Weakness
The convergent corticospinal-tract axonopathy produces the cardinal clinical syndrome: insidiously progressive bilateral lower-limb spasticity and weakness with hyperreflexia, crossed adductor signs, and extensor plantar (Babinski) responses. Spasticity is greatest in hamstring, quadriceps, adductor, and gastrocnemius-soleus muscles; weakness is most prominent in iliopsoas, hamstring, and tibialis anterior. This is the shared functional consequence of all genetic forms of HSP.
Neuron projection (axon) maintenance failure GO:1990535 ↓ DECREASED
Show evidence (1 reference)
PMID:23897027 SUPPORT Human Clinical
"Hypperreflexia, crossed adductor signs, extensor plantar responses are typically present"
Documents the pyramidal signs that result from corticospinal-tract degeneration.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Hereditary Spastic Paraplegia Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

13
Genitourinary 1
Urinary Urgency FREQUENT Urinary urgency HP:0000012
Show evidence (1 reference)
PMID:20301339 SUPPORT Human Clinical
"Sphincter disturbances are very common."
Sphincter disturbances (urinary urgency) are very common in SPAST-HSP.
Limbs 1
Pes Cavus OCCASIONAL Pes cavus HP:0001761
Show evidence (1 reference)
PMID:23897027 SUPPORT Human Clinical
"Although pes cavus is frequent in HSP, it may be absent even in clearly affected subjects."
Pes cavus is a frequent but variable skeletal feature of HSP.
Musculoskeletal 1
Spastic Paraplegia VERY_FREQUENT Spastic paraplegia HP:0001258
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:20301339 SUPPORT Human Clinical
"Spastic paraplegia 4 (SPG4; also known as SPAST-HSP) is characterized by insidiously progressive bilateral lower-limb gait spasticity."
Insidiously progressive lower-limb gait spasticity is the defining clinical feature.
Nervous System 4
Hyperreflexia VERY_FREQUENT Hyperreflexia HP:0001347
Show evidence (1 reference)
PMID:23897027 SUPPORT Human Clinical
"Mild upper extremity hyperreflexia, without increased muscle tone, weakness, or impaired dexterity is common in subjects with uncomplicated HSP."
Hyperreflexia, including upper-limb hyperreflexia, is a typical pyramidal sign in HSP.
Cognitive Impairment FREQUENT Cognitive impairment HP:0100543
Show evidence (1 reference)
PMID:20301389 SUPPORT Human Clinical
"mild intellectual disability with learning difficulties in childhood and/or progressive cognitive decline"
Cognitive impairment is a frequent complicating feature of SPG11 complex HSP.
Peripheral Neuropathy OCCASIONAL Peripheral neuropathy HP:0009830
Show evidence (1 reference)
PMID:20301389 SUPPORT Human Clinical
"peripheral neuropathy"
Peripheral neuropathy is a recognized complicating feature of SPG11.
Cerebellar Ataxia OCCASIONAL Ataxia HP:0001251
Show evidence (1 reference)
PMID:23897027 SUPPORT Human Clinical
"ataxia in SPG7 HSP"
Ataxia is a frequent complicating feature of SPG7 complex HSP.
Other 6
Lower Limb Spasticity VERY_FREQUENT Lower limb spasticity HP:0002061
Show evidence (1 reference)
PMID:33439395 SUPPORT Human Clinical
"Hereditary spastic paraplegias (HSPs) are a group of neurodegenerative disorders which involve the corticospinal tracts and present with distinct spasticity and weakness of the lower extremities."
Lower-extremity spasticity is a presenting hallmark of HSP.
Lower Limb Weakness FREQUENT Lower limb muscle weakness HP:0007340
Show evidence (1 reference)
PMID:20301339 SUPPORT Human Clinical
"More than 50% of affected individuals have some weakness in the legs"
Quantifies lower-limb weakness as frequent in SPAST-HSP.
Extensor Plantar Responses FREQUENT Babinski sign HP:0003487
Show evidence (1 reference)
PMID:23897027 SUPPORT Human Clinical
"extensor plantar responses are typically present (plantar responses may occasionally be absent)."
Extensor plantar responses are typically present, reflecting corticospinal-tract dysfunction.
Impaired Vibration Sense FREQUENT Impaired vibration sensation at ankles HP:0006938
Show evidence (1 reference)
PMID:20301339 SUPPORT Human Clinical
"More than 50% of affected individuals have some weakness in the legs and impaired vibration sense at the ankles."
Impaired ankle vibration sense reflects the dorsal-column involvement characteristic of HSP.
Thin Corpus Callosum OCCASIONAL Thin corpus callosum HP:0033725
Show evidence (1 reference)
PMID:20301389 SUPPORT Human Clinical
"characteristic brain MRI features that include thinning of the corpus callosum."
Thin corpus callosum is a characteristic neuroimaging feature of SPG11 complex HSP.
Distal Amyotrophy OCCASIONAL Distal amyotrophy HP:0003693
Show evidence (1 reference)
PMID:23897027 SUPPORT Human Clinical
"Lower motor neuron involvement, evident as distal muscle wasting is common in a many genetic types of HSP"
Distal amyotrophy reflects lower-motor-neuron involvement in several complex HSP types.
🧬

Genetic Associations

4
SPAST
Gene: SPAST hgnc:11233
Autosomal Dominant
Show evidence (1 reference)
PMID:18202664 SUPPORT In Vitro
"Spastin, the most common locus for mutations in hereditary spastic paraplegias"
SPAST/spastin is the most common HSP gene, encoding a microtubule-severing ATPase.
ATL1
Gene: ATL1 hgnc:11231
Autosomal Dominant
Show evidence (1 reference)
PMID:20862796 SUPPORT Human Clinical
"The diagnosis of ATL1-HSP is established in a proband with suggestive findings and almost exclusively a heterozygous pathogenic variant in ATL1 identified by molecular genetic testing."
ATL1 heterozygous variants cause SPG3A, the common early-childhood autosomal dominant HSP.
SPG7
Gene: SPG7 hgnc:11237
Autosomal Recessive
Show evidence (1 reference)
PMID:9635427 SUPPORT Human Clinical
"Two additional Paraplegin mutations, both resulting in a frameshift, were found in a complicated and in a pure form of HSP."
SPG7/paraplegin mutations cause both pure and complicated recessive HSP.
SPG11
Gene: SPG11 hgnc:11226
Autosomal Recessive
Show evidence (1 reference)
PMID:20301389 SUPPORT Human Clinical
"The diagnosis of SPG11 is established in a proband with characteristic clinical and MRI findings and biallelic pathogenic variants in SPG11 identified on molecular genetic testing."
Biallelic SPG11 variants cause the common complex autosomal recessive HSP.
💊

Medical Actions

4
Antispastic Pharmacotherapy (Baclofen / Tizanidine)
Action: Pharmacotherapy NCIT:C15986
Agent: baclofen CHEBI:2972 tizanidine CHEBI:63629
Oral antispastic drugs, principally baclofen and tizanidine, are used to reduce lower-limb spasticity. Treatment is symptomatic; no therapy prevents the underlying axonal degeneration. Note: in SPG3A (ATL1-HSP), GeneReviews advises avoiding dantrolene because it can induce irreversible weakness adversely affecting mobility.
Target Phenotypes: Lower limb spasticity HP:0002061
Show evidence (2 references)
PMID:20301339 SUPPORT Human Clinical
"Antispastic drugs for leg spasticity"
GeneReviews recommends antispastic drugs for leg spasticity in HSP.
PMID:20862796 SUPPORT Human Clinical
"Medical treatment of spasticity may begin with oral baclofen or tizanidine"
Identifies oral baclofen or tizanidine as first-line antispastic agents.
Botulinum Toxin and Intrathecal Baclofen
Action: Pharmacotherapy NCIT:C15986
Agent: botulinum toxin type A CHEBI:3160 baclofen CHEBI:2972
For severe, disabling spasticity when oral drugs are ineffective or not tolerated, focal chemodenervation with botulinum toxin and intrathecal baclofen via implanted pump are considered.
Target Phenotypes: Lower limb spasticity HP:0002061
Show evidence (1 reference)
PMID:20301339 SUPPORT Human Clinical
"Consideration of botulinum toxin and intrathecal baclofen when oral drugs are ineffective and spasticity is severe and disabling."
Botulinum toxin and intrathecal baclofen are reserved for severe spasticity refractory to oral drugs.
Physical Therapy
Action: Physical Therapy NCIT:C15302
Regular physiotherapy to stretch spastic muscles and prevent contractures is a mainstay of HSP management, combined with management of foot deformities and ankle-foot orthoses for distal weakness.
Show evidence (1 reference)
PMID:20301339 SUPPORT Human Clinical
"regular physiotherapy to stretch spastic muscles and prevent contractures."
Regular physiotherapy to stretch spastic muscles and prevent contractures is standard HSP management.
Anticholinergic Therapy for Urinary Urgency
Action: Pharmacotherapy NCIT:C15986
Agent: oxybutynin CHEBI:7856
Anticholinergic antispasmodic drugs such as oxybutynin are used to treat urinary urgency from neurogenic bladder, with urodynamic evaluation to guide treatment.
Target Phenotypes: Urinary urgency HP:0000012
Show evidence (1 reference)
PMID:20301339 SUPPORT Human Clinical
"anticholinergic antispasmodic drugs for urinary urgency"
Anticholinergic antispasmodic drugs treat urinary urgency in HSP.
{ }

Source YAML

click to show 
name: Hereditary Spastic Paraplegia
creation_date: "2026-06-08T00:00:00Z"
category: Mendelian
description: >
  Hereditary spastic paraplegia (HSP) is a clinically and genetically
  heterogeneous group of inherited neurodegenerative disorders unified by
  length-dependent distal axonal degeneration of the corticospinal-tract upper
  motor neurons, maximal at the distal ends of the longest central nervous
  system axons in the thoracic spinal cord, with accompanying degeneration of
  the fasciculus gracilis (dorsal column) sensory fibers. More than 80 spastic
  paraplegia (SPG) genetic loci have been described, encoding proteins with
  diverse functions including axonal transport (SPAST/spastin microtubule
  severing), endoplasmic reticulum morphogenesis (ATL1/atlastin-1,
  SPAST/spastin, REEP1), mitochondrial quality control and oxidative
  phosphorylation (SPG7/paraplegin), and lipid/membrane and lysosomal-endosomal
  trafficking (SPG11/spatacsin). Despite this molecular diversity, the converging
  pathology is relatively selective corticospinal-tract axonopathy producing the
  shared clinical syndrome of progressive lower-limb spasticity and weakness with
  hyperreflexia and extensor plantar responses. HSP is divided clinically into
  "pure" (uncomplicated) forms, in which spasticity and weakness of the legs with
  subtle dorsal-column impairment and urinary urgency are the only features, and
  "complex" (complicated) forms, in which spastic paraplegia is accompanied by
  additional neurologic or systemic features such as thin corpus callosum,
  cognitive decline, peripheral neuropathy, ataxia, or distal amyotrophy.
disease_term:
  preferred_term: hereditary spastic paraplegia
  term:
    id: MONDO:0019064
    label: hereditary spastic paraplegia
references:
- reference: PMID:20301682
  title: "Uncomplicated (Pure) Hereditary Spastic Paraplegia Overview."
  tags:
  - GeneReviews
- reference: PMID:20301339
  title: "Spastic Paraplegia 4."
  tags:
  - GeneReviews
- reference: PMID:20301389
  title: "Spastic Paraplegia 11."
  tags:
  - GeneReviews
- reference: PMID:20862796
  title: "Spastic Paraplegia 3A."
  tags:
  - GeneReviews

has_subtypes:
- name: Pure HSP
  display_name: Pure (Uncomplicated) Hereditary Spastic Paraplegia
  description: >
    Clinical classification in which lower-extremity spasticity and weakness,
    with subtle lower-extremity dorsal-column (vibration sense) impairment and
    urinary urgency, are the predominant or only manifestations. Affected
    individuals typically have normal life expectancy and do not develop
    significant upper-extremity, bulbar, or cognitive involvement. SPG4
    (SPAST) is the prototypical and single most common cause of pure autosomal
    dominant HSP.
  evidence:
  - reference: PMID:23897027
    reference_title: "Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "“uncomplicated” (characterized by lower extremity spasticity and weakness and subtle lower extremity dorsal column impairment)"
    explanation: Defines the pure/uncomplicated HSP clinical category by its restricted feature set.
- name: Complex HSP
  display_name: Complex (Complicated) Hereditary Spastic Paraplegia
  description: >
    Clinical classification in which spastic paraplegia is associated with
    additional neurologic or systemic abnormalities, including dementia or
    cognitive impairment, ataxia, intellectual disability, peripheral
    neuropathy, distal wasting, loss of vision, epilepsy, ichthyosis, or thin
    corpus callosum on neuroimaging. SPG11 (spatacsin) is a common autosomal
    recessive cause of complex HSP. Correlation between the clinical
    pure-versus-complex split and the underlying genetic type is imperfect,
    and many genetic types can present as either form.
  evidence:
  - reference: PMID:23897027
    reference_title: "Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "“complicated” (in which spastic paraplegia is associated with additional neurologic or systemic abnormalities including dementia, ataxia, mental retardation, neuropathy, distal wasting, loss of vision, epilepsy, or icthyosis"
    explanation: Defines the complex/complicated HSP clinical category by the spectrum of additional features.
  - reference: PMID:23897027
    reference_title: "Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is imperfect correlation between clinical classification (“uncomplicated” versus “complicated”) and genetic types of HSP."
    explanation: Notes that the pure-versus-complex clinical split does not map cleanly onto genetic subtype.
- name: SPG4
  display_name: Spastic Paraplegia 4 (SPAST-HSP)
  description: >
    Autosomal dominant HSP caused by heterozygous pathogenic variants in SPAST,
    encoding the microtubule-severing AAA ATPase spastin. SPG4 is the single
    most common form of autosomal dominant HSP and is the prototype of pure
    HSP, though dementia, ataxia, thin corpus callosum, and muscle wasting have
    been reported. Onset is insidious, mostly in young adulthood, with
    considerable intrafamilial variation.
  genes:
  - preferred_term: SPAST
    term:
      id: hgnc:11233
      label: SPAST
  inheritance:
  - name: Autosomal Dominant (SPG4)
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:20301339
    reference_title: "Spastic Paraplegia 4."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Spastic paraplegia 4 (SPG4; also known as SPAST-HSP) \nis characterized by insidiously progressive bilateral lower-limb gait \nspasticity."
    explanation: GeneReviews establishes SPG4/SPAST-HSP as a distinct autosomal dominant HSP subtype.
- name: SPG3A
  display_name: Spastic Paraplegia 3A (ATL1-HSP)
  description: >
    Autosomal dominant HSP caused by heterozygous pathogenic variants in ATL1,
    encoding atlastin-1, a dynamin-like GTPase that mediates homotypic fusion of
    endoplasmic reticulum tubules. SPG3A is the most common cause of early
    childhood-onset autosomal dominant HSP, with average age of onset around
    four years and a relatively slow, often non-progressive course. Usually a
    pure HSP, but complicated forms with axonal motor neuropathy and distal
    amyotrophy (Silver syndrome phenotype) occur.
  genes:
  - preferred_term: ATL1
    term:
      id: hgnc:11231
      label: ATL1
  inheritance:
  - name: Autosomal Dominant (SPG3A)
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:20862796
    reference_title: "Spastic Paraplegia 3A."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Spastic paraplegia 3A (SPG3A; also known as ATL1-HSP) \nis characterized by progressive bilateral and mostly symmetric spasticity and \nweakness of the legs."
    explanation: GeneReviews establishes SPG3A/ATL1-HSP as a distinct autosomal dominant HSP subtype.
  - reference: PMID:20862796
    reference_title: "Spastic Paraplegia 3A."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The average age of onset is four years. More \nthan 80% of reported individuals manifest spastic gait before the end of the \nfirst decade of life."
    explanation: Documents the characteristic early-childhood onset distinguishing SPG3A.
- name: SPG7
  display_name: Spastic Paraplegia 7 (SPG7/paraplegin)
  description: >
    Most commonly autosomal recessive HSP caused by biallelic pathogenic
    variants in SPG7, encoding paraplegin, a nuclear-encoded mitochondrial
    metalloprotease (m-AAA protease) of the inner mitochondrial membrane.
    SPG7-HSP frequently presents as complex HSP with cerebellar ataxia,
    ophthalmoplegia/ptosis, optic atrophy, and mitochondrial cytopathy on
    muscle biopsy, reflecting oxidative-phosphorylation impairment, but pure
    forms also occur. Some heterozygous SPG7 variants have been associated with
    dominantly transmitted disease.
  genes:
  - preferred_term: SPG7
    term:
      id: hgnc:11237
      label: SPG7
  inheritance:
  - name: Autosomal Recessive (SPG7)
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:9635427
    reference_title: "Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found that patients from a chromosome 16q24.3-linked HSP family are homozygous \nfor a 9.5 kb deletion involving a gene encoding a novel protein, named \nParaplegin."
    explanation: Original identification of recessive SPG7 caused by biallelic paraplegin mutations.
  - reference: PMID:23897027
    reference_title: "Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SPG7 HSP was originally described as an autosomal recessive disorder due to homozygous or compound heterozygous SPG7/paraplegin gene mutations."
    explanation: Confirms SPG7 as predominantly autosomal recessive HSP.
- name: SPG11
  display_name: Spastic Paraplegia 11 (SPG11/spatacsin)
  description: >
    Autosomal recessive complex HSP caused by biallelic pathogenic variants in
    SPG11, encoding spatacsin. SPG11 is one of the most common forms of
    autosomal recessive HSP and is characteristically associated with thinning
    of the corpus callosum, mild intellectual disability or progressive
    cognitive decline, peripheral neuropathy, and pseudobulbar involvement.
    Onset is usually in infancy or adolescence, and most affected individuals
    become wheelchair-bound one or two decades after onset.
  genes:
  - preferred_term: SPG11
    term:
      id: hgnc:11226
      label: SPG11
  inheritance:
  - name: Autosomal Recessive (SPG11)
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:20301389
    reference_title: "Spastic Paraplegia 11."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Spastic paraplegia 11 (SPG11) is characterized by \nprogressive spasticity and weakness of the lower limbs frequently associated \nwith the following: mild intellectual disability with learning difficulties in \nchildhood and/or progressive cognitive decline; peripheral neuropathy; \npseudobulbar involvement; and increased reflexes in the upper limbs."
    explanation: GeneReviews establishes SPG11 as a distinct complex autosomal recessive HSP subtype.

pathophysiology:
- name: Length-Dependent Corticospinal-Tract Axonal Degeneration
  description: >
    The unifying pathology of HSP is degeneration of the lateral corticospinal
    tract axons, maximal at their distal ends in the thoracic spinal cord, with
    accompanying degeneration of the fasciculus gracilis (dorsal column) sensory
    fibers maximal in the cervico-medullary region. This pattern reflects a
    selective vulnerability of the longest motor and sensory axons of the central
    nervous system, a length-dependent distal axonopathy of the upper motor
    neuron. The diverse molecular causes of HSP converge on this relatively
    uniform corticospinal-tract degeneration, producing the shared clinical
    syndrome of progressive lower-limb spasticity and weakness.
  cell_types:
  - preferred_term: Upper motor neuron (corticospinal tract)
    term:
      id: CL:0008048
      label: upper motor neuron
  - preferred_term: Betz upper motor neuron
    term:
      id: CL:4023052
      label: Betz upper motor neuron
  locations:
  - preferred_term: Lateral corticospinal tract
    term:
      id: UBERON:0002589
      label: lateral corticospinal tract
  - preferred_term: Corticospinal tract
    term:
      id: UBERON:0002707
      label: corticospinal tract
  biological_processes:
  - preferred_term: Neuron projection (axon) maintenance failure
    term:
      id: GO:1990535
      label: neuron projection maintenance
    modifier: DECREASED
  downstream:
  - target: Progressive Lower-Limb Spasticity and Weakness
  evidence:
  - reference: PMID:23897027
    reference_title: "Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Postmortem studies consistently identify degeneration of corticospinal tract \naxons (maximal in the thoracic spinal cord) and degeneration of fasciculus \ngracilis fibers (maximal in the cervico-medullary region)."
    explanation: Establishes the consistent corticospinal-tract and dorsal-column degeneration that defines HSP neuropathology.
  - reference: PMID:23897027
    reference_title: "Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HSP syndromes thus \nappear to involve motor-sensory axon degeneration affecting predominantly (but \nnot exclusively) the distal ends of long central nervous system (CNS) axons."
    explanation: Supports the length-dependent distal axonopathy concept central to HSP pathogenesis.
  - reference: PMID:33439395
    reference_title: "Hereditary spastic paraplegia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common neuropathological sign \nis the axonal degeneration involving the lateral corticospinal tracts in both \nthe cervical and thoracic spinal cord."
    explanation: Independent review confirms lateral corticospinal-tract axonal degeneration as the dominant neuropathology.
- name: Spastin Microtubule-Severing Defect (SPG4)
  description: >
    Spastin, encoded by SPAST (SPG4), is a microtubule-severing AAA ATPase that
    assembles into a hexameric ring and remodels neuronal microtubule arrays by
    pulling the C-terminal tail of tubulin through its central pore to generate
    a mechanical force that destabilizes the microtubule lattice. Pathogenic
    SPAST variants impair this severing activity, disrupting the dynamic
    microtubule cytoskeleton required for axonal transport and organelle
    distribution in long corticospinal-tract axons. Spastin loss-of-function
    also disrupts cytoarchitectural integrity and organellar stability
    (mitochondrial and ER) in corticospinal motor neurons, contributing to
    selective UMN vulnerability.
  cell_types:
  - preferred_term: Upper motor neuron (corticospinal tract)
    term:
      id: CL:0008048
      label: upper motor neuron
  biological_processes:
  - preferred_term: Microtubule severing
    term:
      id: GO:0051013
      label: microtubule severing
    modifier: DECREASED
  - preferred_term: Axonal transport
    term:
      id: GO:0098930
      label: axonal transport
    modifier: DECREASED
  - preferred_term: Mitochondrion organization
    term:
      id: GO:0007005
      label: mitochondrion organization
    modifier: DECREASED
  - preferred_term: Endoplasmic reticulum organization
    term:
      id: GO:0007029
      label: endoplasmic reticulum organization
    modifier: DECREASED
  downstream:
  - target: Length-Dependent Corticospinal-Tract Axonal Degeneration
  evidence:
  - reference: PMID:18202664
    reference_title: "Structural basis of microtubule severing by the hereditary spastic paraplegia protein spastin."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Spastin, the most common locus for mutations in hereditary spastic paraplegias, \nand katanin are related microtubule-severing AAA ATPases"
    explanation: Identifies spastin as a microtubule-severing AAA ATPase and the most common HSP locus.
  - reference: PMID:18202664
    reference_title: "Structural basis of microtubule severing by the hereditary spastic paraplegia protein spastin."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "our data support a model in which spastin pulls the C terminus of \ntubulin through its central pore, generating a mechanical force that \ndestabilizes tubulin-tubulin interactions within the microtubule lattice."
    explanation: Defines the molecular mechanism of spastin-mediated microtubule severing disrupted in SPG4.
  - reference: PMID:42320547
    reference_title: "Proteomic analysis reveals early pathological defects in corticospinal motor neurons of a spastin model of hereditary spastic paraplegia, which are improved by NU-9 treatment."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "limitations with cytoarchitectural integrity and stability of key organelles contribute to their neuronal vulnerability"
    explanation: Proteomic analysis of SPASTC448Y mice reveals that spastin loss-of-function causes early cytoarchitectural defects and organellar instability contributing to corticospinal neuron vulnerability.
  - reference: PMID:42320547
    reference_title: "Proteomic analysis reveals early pathological defects in corticospinal motor neurons of a spastin model of hereditary spastic paraplegia, which are improved by NU-9 treatment."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "NU-9 treatment (100 mg/kg, for 100 days) significantly prevented degeneration of corticospinal axons, restored the integrity of mitochondria and endoplasmic reticulum, and reduced the presence of electron-dense accumulations in the CSMN of SPASTC448Y mice."
    explanation: Demonstrates that spastin dysfunction specifically compromises mitochondrial and ER integrity in corticospinal motor neurons, and restoration of these organellar functions prevents axonal degeneration.
- name: Atlastin-1 ER Tubular Network Defect (SPG3A)
  description: >
    Atlastin-1, encoded by ATL1 (SPG3A), is a dynamin-like, integral-membrane
    GTPase that mediates homotypic fusion of endoplasmic reticulum tubules and
    is required for proper formation of the interconnected tubular ER network.
    ATL1 pathogenic variants impair ER-tubule fusion and network formation;
    because spastin, atlastin, REEP1, and reticulon-2 interact in shaping the
    tubular ER, ER-shaping defects are proposed as a shared neuropathogenic
    mechanism converging on corticospinal-tract axon degeneration.
  cell_types:
  - preferred_term: Upper motor neuron (corticospinal tract)
    term:
      id: CL:0008048
      label: upper motor neuron
  cellular_components:
  - preferred_term: Endoplasmic reticulum tubular network
    term:
      id: GO:0071782
      label: endoplasmic reticulum tubular network
  biological_processes:
  - preferred_term: Endoplasmic reticulum membrane fusion
    term:
      id: GO:0016320
      label: endoplasmic reticulum membrane fusion
    modifier: DECREASED
  - preferred_term: Endoplasmic reticulum tubular network organization
    term:
      id: GO:0071786
      label: endoplasmic reticulum tubular network organization
    modifier: DECREASED
  downstream:
  - target: Length-Dependent Corticospinal-Tract Axonal Degeneration
  evidence:
  - reference: PMID:19665976
    reference_title: "A class of dynamin-like GTPases involved in the generation of the tubular ER network."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "we show that mammalian atlastins, which are dynamin-like, \nintegral membrane GTPases, interact with the tubule-shaping proteins. The \natlastins localize to the tubular ER and are required for proper network \nformation in vivo and in vitro."
    explanation: Establishes atlastin's role in forming the tubular ER network, disrupted in SPG3A.
  - reference: PMID:19665976
    reference_title: "A class of dynamin-like GTPases involved in the generation of the tubular ER network."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Since atlastin-1 mutations cause a common form of hereditary spastic paraplegia, \nwe suggest ER-shaping defects as a neuropathogenic mechanism."
    explanation: Directly links atlastin-1 mutations and HSP to ER-shaping defects as the proposed mechanism.
- name: Paraplegin Mitochondrial Quality-Control and OXPHOS Failure (SPG7)
  description: >
    Paraplegin, encoded by SPG7, is a nuclear-encoded mitochondrial
    metalloprotease (m-AAA protease) embedded in the inner mitochondrial
    membrane, where it maintains mitochondrial protein quality by degrading
    damaged or unassembled respiratory-chain subunits. Loss of paraplegin
    function impairs oxidative phosphorylation; SPG7 patient cells show
    fragmented mitochondria, reduced mitochondrial mass and membrane potential,
    impaired oxidative phosphorylation with reduced ATP, and increased
    mitochondrial oxidative stress, providing a bioenergetic mechanism for
    corticospinal-tract neurodegeneration.
  cell_types:
  - preferred_term: Upper motor neuron (corticospinal tract)
    term:
      id: CL:0008048
      label: upper motor neuron
  biological_processes:
  - preferred_term: Mitochondrial protein quality control
    term:
      id: GO:0141164
      label: mitochondrial protein quality control
    modifier: DECREASED
  - preferred_term: Oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  downstream:
  - target: Length-Dependent Corticospinal-Tract Axonal Degeneration
  evidence:
  - reference: PMID:9635427
    reference_title: "Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Analysis of muscle biopsies from two \npatients carrying Paraplegin mutations showed typical signs of mitochondrial \nOXPHOS defects, thus suggesting a mechanism for neurodegeneration in HSP-type \ndisorders."
    explanation: Links paraplegin mutations to oxidative-phosphorylation defects as the neurodegenerative mechanism in SPG7.
  - reference: PMID:32973427
    reference_title: "Mitochondrial Function in Hereditary Spastic Paraplegia: Deficits in SPG7 but Not SPAST Patient-Derived Stem Cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "SPG7 \npatient cells had increased paraplegin expression, fragmented mitochondria with \nlow interconnectivity, reduced mitochondrial mass, decreased mitochondrial \nmembrane potential, reduced oxidative phosphorylation, reduced ATP content, \nincreased mitochondrial oxidative stress, and reduced cellular proliferation."
    explanation: Patient-derived SPG7 cells show the mitochondrial dysfunction phenotype underlying neurodegeneration.
  - reference: PMID:32973427
    reference_title: "Mitochondrial Function in Hereditary Spastic Paraplegia: Deficits in SPG7 but Not SPAST Patient-Derived Stem Cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Mitochondrial dysfunction was specific to SPG7 patient cells and not present in \nSPAST patient cells, which displayed mitochondrial functions similar to control \ncells."
    explanation: Demonstrates genotype-specific mitochondrial pathology, distinguishing the SPG7 mechanism from SPG4/SPAST.

- name: Progressive Lower-Limb Spasticity and Weakness
  description: >
    The convergent corticospinal-tract axonopathy produces the cardinal clinical
    syndrome: insidiously progressive bilateral lower-limb spasticity and
    weakness with hyperreflexia, crossed adductor signs, and extensor plantar
    (Babinski) responses. Spasticity is greatest in hamstring, quadriceps,
    adductor, and gastrocnemius-soleus muscles; weakness is most prominent in
    iliopsoas, hamstring, and tibialis anterior. This is the shared functional
    consequence of all genetic forms of HSP.
  biological_processes:
  - preferred_term: Neuron projection (axon) maintenance failure
    term:
      id: GO:1990535
      label: neuron projection maintenance
    modifier: DECREASED
  evidence:
  - reference: PMID:23897027
    reference_title: "Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hypperreflexia, crossed adductor signs, extensor plantar responses are typically present"
    explanation: Documents the pyramidal signs that result from corticospinal-tract degeneration.

phenotypes:
- category: Neurologic
  name: Spastic Paraplegia
  description: >
    Progressive bilateral lower-limb gait spasticity is the cardinal and
    defining feature of HSP, resulting from corticospinal-tract degeneration.
  phenotype_term:
    preferred_term: Spastic paraplegia
    term:
      id: HP:0001258
      label: Spastic paraplegia
    clinical_course: PROGRESSIVE
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:20301339
    reference_title: "Spastic Paraplegia 4."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Spastic paraplegia 4 (SPG4; also known as SPAST-HSP) \nis characterized by insidiously progressive bilateral lower-limb gait \nspasticity."
    explanation: Insidiously progressive lower-limb gait spasticity is the defining clinical feature.
- category: Neurologic
  name: Lower Limb Spasticity
  description: >
    Increased muscle tone in the legs, greatest in hamstring, quadriceps,
    adductor, and gastrocnemius-soleus muscles.
  phenotype_term:
    preferred_term: Lower limb spasticity
    term:
      id: HP:0002061
      label: Lower limb spasticity
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:33439395
    reference_title: "Hereditary spastic paraplegia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hereditary spastic paraplegias (HSPs) are a group of neurodegenerative disorders \nwhich involve the corticospinal tracts and present with distinct spasticity and \nweakness of the lower extremities."
    explanation: Lower-extremity spasticity is a presenting hallmark of HSP.
- category: Neurologic
  name: Lower Limb Weakness
  description: >
    Weakness of the legs, most prominent in iliopsoas, hamstring, and tibialis
    anterior muscles; more than 50% of affected individuals have some leg
    weakness.
  phenotype_term:
    preferred_term: Lower limb muscle weakness
    term:
      id: HP:0007340
      label: Lower limb muscle weakness
  frequency: FREQUENT
  evidence:
  - reference: PMID:20301339
    reference_title: "Spastic Paraplegia 4."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "More \nthan 50% of affected individuals have some weakness in the legs"
    explanation: Quantifies lower-limb weakness as frequent in SPAST-HSP.
- category: Neurologic
  name: Hyperreflexia
  description: >
    Brisk deep-tendon reflexes in the lower limbs (and frequently mild
    upper-limb hyperreflexia) reflecting upper-motor-neuron involvement.
  phenotype_term:
    preferred_term: Hyperreflexia
    term:
      id: HP:0001347
      label: Hyperreflexia
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:23897027
    reference_title: "Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mild upper extremity hyperreflexia, without increased muscle tone, weakness, or impaired dexterity is common in subjects with uncomplicated HSP."
    explanation: Hyperreflexia, including upper-limb hyperreflexia, is a typical pyramidal sign in HSP.
- category: Neurologic
  name: Extensor Plantar Responses
  description: >
    Babinski sign (extensor plantar response) is a typical upper-motor-neuron
    sign in HSP.
  phenotype_term:
    preferred_term: Babinski sign
    term:
      id: HP:0003487
      label: Babinski sign
  frequency: FREQUENT
  evidence:
  - reference: PMID:23897027
    reference_title: "Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "extensor plantar responses are typically present (plantar responses may occasionally be absent)."
    explanation: Extensor plantar responses are typically present, reflecting corticospinal-tract dysfunction.
- category: Neurologic
  name: Impaired Vibration Sense
  description: >
    Mild impairment of vibration sensation at the ankles/toes, reflecting
    subtle dorsal-column (fasciculus gracilis) involvement.
  phenotype_term:
    preferred_term: Impaired vibration sensation at ankles
    term:
      id: HP:0006938
      label: Impaired vibration sensation at ankles
  frequency: FREQUENT
  evidence:
  - reference: PMID:20301339
    reference_title: "Spastic Paraplegia 4."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "More \nthan 50% of affected individuals have some weakness in the legs and impaired vibration sense at the ankles."
    explanation: Impaired ankle vibration sense reflects the dorsal-column involvement characteristic of HSP.
- category: Genitourinary
  name: Urinary Urgency
  description: >
    Sphincter disturbances, particularly urinary urgency from neurogenic
    bladder, are very common and occasionally a presenting feature.
  phenotype_term:
    preferred_term: Urinary urgency
    term:
      id: HP:0000012
      label: Urinary urgency
  frequency: FREQUENT
  evidence:
  - reference: PMID:20301339
    reference_title: "Spastic Paraplegia 4."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sphincter disturbances are very \ncommon."
    explanation: Sphincter disturbances (urinary urgency) are very common in SPAST-HSP.
- category: Neurologic
  name: Thin Corpus Callosum
  description: >
    Thinning of the corpus callosum on brain MRI is a characteristic feature of
    complex HSP, most strongly associated with SPG11 but also seen in SPG3A,
    SPG4, SPG7, and others.
  phenotype_term:
    preferred_term: Thin corpus callosum
    term:
      id: HP:0033725
      label: Thin corpus callosum
  subtype: Complex HSP
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:20301389
    reference_title: "Spastic Paraplegia 11."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "characteristic brain MRI features that include thinning of the corpus callosum."
    explanation: Thin corpus callosum is a characteristic neuroimaging feature of SPG11 complex HSP.
- category: Neurologic
  name: Cognitive Impairment
  description: >
    Mild intellectual disability with learning difficulties in childhood and/or
    progressive cognitive decline, characteristic of complex HSP, especially
    SPG11.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  subtype: Complex HSP
  frequency: FREQUENT
  evidence:
  - reference: PMID:20301389
    reference_title: "Spastic Paraplegia 11."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mild intellectual disability with learning difficulties in \nchildhood and/or progressive cognitive decline"
    explanation: Cognitive impairment is a frequent complicating feature of SPG11 complex HSP.
- category: Neurologic
  name: Peripheral Neuropathy
  description: >
    Peripheral (often axonal motor-sensory) neuropathy is a complicating feature
    in more than a dozen genetic types of HSP, including SPG11 and a subset of
    SPG3A.
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  subtype: Complex HSP
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:20301389
    reference_title: "Spastic Paraplegia 11."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "peripheral neuropathy"
    explanation: Peripheral neuropathy is a recognized complicating feature of SPG11.
- category: Neurologic
  name: Cerebellar Ataxia
  description: >
    Cerebellar signs including ataxia are a complicating feature of HSP,
    frequent in SPG7 and reported in SPG11.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  subtype: Complex HSP
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:23897027
    reference_title: "Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ataxia in SPG7 HSP"
    explanation: Ataxia is a frequent complicating feature of SPG7 complex HSP.
- category: Musculoskeletal
  name: Pes Cavus
  description: >
    High-arched foot deformity (pes cavus) is frequent in HSP, although it may
    be absent even in clearly affected individuals.
  phenotype_term:
    preferred_term: Pes cavus
    term:
      id: HP:0001761
      label: Pes cavus
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:23897027
    reference_title: "Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although pes cavus is frequent in HSP, it may be absent even in clearly affected subjects."
    explanation: Pes cavus is a frequent but variable skeletal feature of HSP.
- category: Neurologic
  name: Distal Amyotrophy
  description: >
    Distal muscle wasting (lower-motor-neuron involvement) is common in several
    genetic types of HSP, notably SPG10, SPG17 (Silver syndrome), and SPG20
    (Troyer syndrome), and may occur in SPG11.
  phenotype_term:
    preferred_term: Distal amyotrophy
    term:
      id: HP:0003693
      label: Distal amyotrophy
  subtype: Complex HSP
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:23897027
    reference_title: "Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lower motor neuron involvement, evident as distal muscle wasting is common in a many genetic types of HSP"
    explanation: Distal amyotrophy reflects lower-motor-neuron involvement in several complex HSP types.

inheritance:
- name: Autosomal Dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >
    Autosomal dominant HSP includes the most common forms SPG4 (SPAST) and
    SPG3A (ATL1). Penetrance is age-dependent and may be high (80-90% in SPG4)
    or as low as 70%.
  evidence:
  - reference: PMID:20301339
    reference_title: "Spastic Paraplegia 4."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SPAST-HSP is inherited in an autosomal dominant manner with \nage-related, nearly complete penetrance"
    explanation: Establishes autosomal dominant inheritance with age-related penetrance for the most common HSP form.
  - reference: PMID:23897027
    reference_title: "Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genetic penetrance in autosomal dominant HSP is age-dependent, may be high (80-90% in SPG4 HSP) or as low as 70%"
    explanation: Quantifies the age-dependent penetrance of autosomal dominant HSP.
- name: Autosomal Recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >
    Autosomal recessive HSP includes SPG7 (paraplegin) and SPG11 (spatacsin),
    which usually present as complex HSP and require biallelic pathogenic
    variants.
  evidence:
  - reference: PMID:20301389
    reference_title: "Spastic Paraplegia 11."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SPG11 is inherited in an autosomal recessive manner."
    explanation: Establishes autosomal recessive inheritance for the common complex HSP form SPG11.

genetic:
- name: SPAST
  gene_term:
    preferred_term: SPAST
    term:
      id: hgnc:11233
      label: SPAST
  subtype: SPG4
  inheritance:
  - name: Autosomal Dominant
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:18202664
    reference_title: "Structural basis of microtubule severing by the hereditary spastic paraplegia protein spastin."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Spastin, the most common locus for mutations in hereditary spastic paraplegias"
    explanation: SPAST/spastin is the most common HSP gene, encoding a microtubule-severing ATPase.
- name: ATL1
  gene_term:
    preferred_term: ATL1
    term:
      id: hgnc:11231
      label: ATL1
  subtype: SPG3A
  inheritance:
  - name: Autosomal Dominant
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:20862796
    reference_title: "Spastic Paraplegia 3A."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of ATL1-HSP is established in a proband with \nsuggestive findings and almost exclusively a heterozygous pathogenic variant in \nATL1 identified by molecular genetic testing."
    explanation: ATL1 heterozygous variants cause SPG3A, the common early-childhood autosomal dominant HSP.
- name: SPG7
  gene_term:
    preferred_term: SPG7
    term:
      id: hgnc:11237
      label: SPG7
  subtype: SPG7
  inheritance:
  - name: Autosomal Recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:9635427
    reference_title: "Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two additional Paraplegin mutations, both resulting in a frameshift, \nwere found in a complicated and in a pure form of HSP."
    explanation: SPG7/paraplegin mutations cause both pure and complicated recessive HSP.
- name: SPG11
  gene_term:
    preferred_term: SPG11
    term:
      id: hgnc:11226
      label: SPG11
  subtype: SPG11
  inheritance:
  - name: Autosomal Recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:20301389
    reference_title: "Spastic Paraplegia 11."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of SPG11 is established in a proband with \ncharacteristic clinical and MRI findings and biallelic pathogenic variants in \nSPG11 identified on molecular genetic testing."
    explanation: Biallelic SPG11 variants cause the common complex autosomal recessive HSP.

treatments:
- name: Antispastic Pharmacotherapy (Baclofen / Tizanidine)
  description: >
    Oral antispastic drugs, principally baclofen and tizanidine, are used to
    reduce lower-limb spasticity. Treatment is symptomatic; no therapy prevents
    the underlying axonal degeneration. Note: in SPG3A (ATL1-HSP), GeneReviews
    advises avoiding dantrolene because it can induce irreversible weakness
    adversely affecting mobility.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: baclofen
      term:
        id: CHEBI:2972
        label: baclofen
    - preferred_term: tizanidine
      term:
        id: CHEBI:63629
        label: tizanidine
  therapeutic_modality: SMALL_MOLECULE
  target_phenotypes:
  - preferred_term: Lower limb spasticity
    term:
      id: HP:0002061
      label: Lower limb spasticity
  evidence:
  - reference: PMID:20301339
    reference_title: "Spastic Paraplegia 4."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Antispastic drugs for leg spasticity"
    explanation: GeneReviews recommends antispastic drugs for leg spasticity in HSP.
  - reference: PMID:20862796
    reference_title: "Spastic Paraplegia 3A."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Medical \ntreatment of spasticity may begin with oral baclofen or tizanidine"
    explanation: Identifies oral baclofen or tizanidine as first-line antispastic agents.
- name: Botulinum Toxin and Intrathecal Baclofen
  description: >
    For severe, disabling spasticity when oral drugs are ineffective or not
    tolerated, focal chemodenervation with botulinum toxin and intrathecal
    baclofen via implanted pump are considered.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: botulinum toxin type A
      term:
        id: CHEBI:3160
        label: Botulinum toxin type A
    - preferred_term: baclofen
      term:
        id: CHEBI:2972
        label: baclofen
  target_phenotypes:
  - preferred_term: Lower limb spasticity
    term:
      id: HP:0002061
      label: Lower limb spasticity
  evidence:
  - reference: PMID:20301339
    reference_title: "Spastic Paraplegia 4."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Consideration of botulinum \ntoxin and intrathecal baclofen when oral drugs are ineffective and spasticity is \nsevere and disabling."
    explanation: Botulinum toxin and intrathecal baclofen are reserved for severe spasticity refractory to oral drugs.
- name: Physical Therapy
  description: >
    Regular physiotherapy to stretch spastic muscles and prevent contractures is
    a mainstay of HSP management, combined with management of foot deformities
    and ankle-foot orthoses for distal weakness.
  treatment_term:
    preferred_term: Physical Therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  therapeutic_modality: BEHAVIORAL
  evidence:
  - reference: PMID:20301339
    reference_title: "Spastic Paraplegia 4."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "regular physiotherapy \nto stretch spastic muscles and prevent contractures."
    explanation: Regular physiotherapy to stretch spastic muscles and prevent contractures is standard HSP management.
- name: Anticholinergic Therapy for Urinary Urgency
  description: >
    Anticholinergic antispasmodic drugs such as oxybutynin are used to treat
    urinary urgency from neurogenic bladder, with urodynamic evaluation to guide
    treatment.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: oxybutynin
      term:
        id: CHEBI:7856
        label: oxybutynin
  therapeutic_modality: SMALL_MOLECULE
  target_phenotypes:
  - preferred_term: Urinary urgency
    term:
      id: HP:0000012
      label: Urinary urgency
  evidence:
  - reference: PMID:20301339
    reference_title: "Spastic Paraplegia 4."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "anticholinergic antispasmodic drugs for urinary urgency"
    explanation: Anticholinergic antispasmodic drugs treat urinary urgency in HSP.

notes: >
  HSP is defined and classified primarily by clinical and genetic features rather
  than neuropathology; more than 80 SPG loci are now recognized. The pure-versus-
  complex clinical split correlates imperfectly with genetic type, and several
  genes (e.g. SPG7) may present as either autosomal dominant or autosomal
  recessive disease. Drug-safety note from GeneReviews (SPG3A/ATL1-HSP):
  dantrolene should be avoided as it can induce irreversible weakness adversely
  affecting mobility.
📚

References & Deep Research

References

4
PMID:20301682
Uncomplicated (Pure) Hereditary Spastic Paraplegia Overview.
No top-level findings curated for this source.
PMID:20301339
Spastic Paraplegia 4.
No top-level findings curated for this source.
PMID:20301389
Spastic Paraplegia 11.
No top-level findings curated for this source.
PMID:20862796
Spastic Paraplegia 3A.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 39 citations 2026-06-08T17:54:54.641658

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Hereditary Spastic Paraplegia
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Hereditary Spastic Paraplegia covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Disease Characteristics Research Report: Hereditary Spastic Paraplegia (HSP)

Target disease

  • Disease name: Hereditary Spastic Paraplegia (HSP) / Hereditary Spastic Paraplegias (HSPs)
  • Category: Mendelian, genetically heterogeneous group of neurodegenerative disorders
  • MONDO ID: Not retrieved in current evidence corpus (see Identifiers table)

Figure (evidence): A 2024 review figure summarizes HSP inheritance modes, representative genes (e.g., SPG4/SPAST, SPG3A/ATL1, SPG11, SPG7), and convergent pathogenic pathways (ER shaping/trafficking, lipid metabolism, mitochondrial/endosomal dysfunction, axonal transport). (awuah2024hereditaryspasticparaplegia media cde30dbb)

1. Disease information

1.1 Concise overview

Hereditary spastic paraplegia (HSP) refers to a group of inherited neurodegenerative disorders whose core clinical syndrome is progressive lower-limb spasticity and weakness, reflecting predominant degeneration of long corticospinal tract fibers (a “dying-back” length-dependent axonopathy). (awuah2024hereditaryspasticparaplegia pages 1-2, cipriano2025fluidbiomarkersin pages 1-2)

A current synthesis frames HSP pathobiology as the convergence of multiple cellular pathways—mitochondrial dysfunction, endoplasmic reticulum (ER) membrane remodeling, autophagy, abnormal myelination, and lipid metabolism alterations, among others—leading to corticospinal tract dysfunction. (awuah2024hereditaryspasticparaplegia pages 1-2)

1.2 Key identifiers and synonyms

A structured identifier lookup (OMIM/Orphanet/ICD/MeSH/MONDO codes) was not directly retrievable from the currently available full-text corpus in this run; therefore, the report explicitly flags missing codes rather than inferring them.

Identifier system Example codes/notes Synonyms/alternate names Comments on scope
OMIM Not retrieved in current corpus for the HSP disease group. Evidence in current corpus supports that HSP is a genetically heterogeneous group with >80 to >90 loci/genes and includes major subtype labels such as SPG4/SPAST, SPG3A/ATL1, SPG11, and SPG7 rather than a single code in the retrieved sources (awuah2024hereditaryspasticparaplegia pages 1-2, cipriano2025fluidbiomarkersin pages 1-2, maccora2024nonpharmacologicaltreatmentof pages 1-2, faccioli2023gaitanalysispatterns pages 1-2). Hereditary spastic paraplegia; hereditary spastic paraplegias; hereditary spastic paraparesis; spastic paraplegia/paraparesis (awuah2024hereditaryspasticparaplegia pages 1-2, maccora2024nonpharmacologicaltreatmentof pages 1-2, faccioli2023gaitanalysispatterns pages 1-2). Primarily a disease-group resource need; many specific OMIM subtype entries likely exist for individual SPG forms, but exact codes were not retrieved in current corpus.
Orphanet Not retrieved in current corpus. Retrieved evidence supports HSP as a rare disease group with multiple Mendelian subtypes, commonly including SPG4/SPAST, SPG3A/ATL1, SPG11, and SPG7 (awuah2024hereditaryspasticparaplegia pages 1-2, cipriano2025fluidbiomarkersin pages 1-2, maccora2024nonpharmacologicaltreatmentof pages 1-2). Hereditary spastic paraplegia; hereditary spastic paraplegias; pure HSP; complicated/complex HSP (cipriano2025fluidbiomarkersin pages 1-2, maccora2024nonpharmacologicaltreatmentof pages 1-2). Disease-group level likely represented in Orphanet, with additional subtype records; exact Orphanet identifiers were not retrieved in current corpus.
ICD-10 / ICD-11 Not retrieved in current corpus. Current evidence emphasizes phenotype-based grouping (pure vs complicated HSP) and subtype labels by SPG number/gene rather than ICD codes (cipriano2025fluidbiomarkersin pages 1-2, maccora2024nonpharmacologicaltreatmentof pages 1-2, faccioli2023gaitanalysispatterns pages 1-2). Hereditary spastic paraplegia; hereditary spastic paraparesis (maccora2024nonpharmacologicaltreatmentof pages 1-2, faccioli2023gaitanalysispatterns pages 1-2). Coding in ICD is expected to be broader/clinical, whereas HSP nosology in the retrieved literature is mainly gene/subtype based.
MeSH Not retrieved in current corpus. No specific MeSH descriptor or tree number was provided in the retrieved evidence (awuah2024hereditaryspasticparaplegia pages 1-2, cipriano2025fluidbiomarkersin pages 1-2). Hereditary spastic paraplegia; hereditary spastic paraplegias (awuah2024hereditaryspasticparaplegia pages 1-2, cipriano2025fluidbiomarkersin pages 1-2). Likely a disease-group heading if present, but exact MeSH identifier was not retrieved in current corpus.
MONDO Exact MONDO identifier not retrieved in current corpus. Based on disease ontology practice and the evidence that HSP is a disease group with many genetic subtypes, it is appropriate to note that MONDO likely contains a hereditary spastic paraplegia group term plus subtype terms; exact IDs were not retrieved here (awuah2024hereditaryspasticparaplegia pages 1-2, cipriano2025fluidbiomarkersin pages 1-2, awuah2024hereditaryspasticparaplegia media cde30dbb). Hereditary spastic paraplegia; hereditary spastic paraplegias (awuah2024hereditaryspasticparaplegia pages 1-2, cipriano2025fluidbiomarkersin pages 1-2). Disease-group term plus subtype terms expected; exact MONDO codes unavailable in current corpus.
SPG4 / SPAST Common autosomal dominant HSP subtype; SPAST/SPG4 is reported as the most prevalent AD-HSP and accounts for about 40–45% of familial cases in one 2024 review; another review notes SPAST as the most common AD gene (awuah2024hereditaryspasticparaplegia pages 1-2, maccora2024nonpharmacologicaltreatmentof pages 1-2). Spastic paraplegia type 4; SPAST-related HSP; SPG4 (awuah2024hereditaryspasticparaplegia pages 1-2, maccora2024nonpharmacologicaltreatmentof pages 1-2). Specific subtype/gene-defined disorder within the broader HSP group.
SPG3A / ATL1 Common autosomal dominant subtype; ATL1/SPG3A is described as the second most common form and about ~7% of AD-HSP in one review; usually childhood-onset and often pure, but severe very-early-onset complex cases are reported (awuah2024hereditaryspasticparaplegia pages 1-2, brozkova2026childrenwithsuspected pages 1-2). Spastic paraplegia type 3A; ATL1-related HSP; SPG3A (awuah2024hereditaryspasticparaplegia pages 1-2, brozkova2026childrenwithsuspected pages 1-2). Specific subtype/gene-defined disorder within the HSP group; usually pure childhood-onset but can be complex.
SPG11 Frequent autosomal recessive subtype; one review reports SPG11 as about ~18% of HSP globally and another identifies SPG11 among the most frequent genotypes in HSP with movement disorders (awuah2024hereditaryspasticparaplegia pages 1-2, azeem2024investigatingthegenetic pages 1-2). Spastic paraplegia type 11; SPG11-related HSP (awuah2024hereditaryspasticparaplegia pages 1-2, azeem2024investigatingthegenetic pages 1-2). Specific subtype/gene-defined disorder within the HSP group; often associated with complicated phenotypes.
SPG7 Frequent autosomal recessive subtype; cited among common genotypes, especially in HSP with movement disorders, and often associated with adult onset, ataxia, extraocular movement abnormalities, and seizures in comparative analyses (cipriano2025fluidbiomarkersin pages 1-2, azeem2024investigatingthegenetic pages 1-2). Spastic paraplegia type 7; SPG7-related HSP (cipriano2025fluidbiomarkersin pages 1-2, azeem2024investigatingthegenetic pages 1-2). Specific subtype/gene-defined disorder within the HSP group; often phenotypically complex.

Table: This table summarizes what the current evidence corpus supports about HSP naming and classification resources. It distinguishes disease-group level identifiers from major gene-defined subtypes and clearly marks identifier codes that were not directly retrieved.

Common synonyms (literature use): - “Hereditary spastic paraplegia”, “hereditary spastic paraplegias”, “hereditary spastic paraparesis”, “spastic paraplegia/paraparesis”. (maccora2024nonpharmacologicaltreatmentof pages 1-2, faccioli2023gaitanalysispatterns pages 1-2)

1.3 Classification and evidence sources

  • Clinical classification (Harding): “pure” (isolated spastic paraparesis +/- urinary symptoms, mild vibration loss) vs “complex/complicated” (additional neurologic/non-neurologic features). (maccora2024nonpharmacologicaltreatmentof pages 1-2)
  • Inheritance: autosomal dominant (AD), autosomal recessive (AR), X-linked, and mitochondrial forms are all described; AD is commonly reported as prominent in European/North American cohorts, and a substantial minority can be sporadic. (maccora2024nonpharmacologicaltreatmentof pages 1-2)

Evidence type: This report synthesizes aggregated disease-level resources (systematic/narrative reviews, meta-analyses, cohort studies, ClinicalTrials.gov records) rather than EHR-only sources. (awuah2024hereditaryspasticparaplegia pages 1-2, maccora2024nonpharmacologicaltreatmentof pages 1-2, faccioli2023gaitanalysispatterns pages 1-2, siow2023outcomemeasuresand pages 1-2, NCT04101643 chunk 1)

2. Etiology

2.1 Primary causal factors

HSP is primarily genetic with marked locus heterogeneity—reported as ~80+ genes/loci in recent reviews, and >90 loci in a 2025 biomarker review. (awuah2024hereditaryspasticparaplegia pages 1-2, cipriano2025fluidbiomarkersin pages 1-2)

Representative high-frequency genes/subtypes and inheritance: - SPG4 / SPAST (AD): most prevalent AD-HSP; one review estimates ~40–45% of familial cases. (awuah2024hereditaryspasticparaplegia pages 1-2) - SPG3A / ATL1 (typically AD): estimated ~7% of AD-HSP in one review; usually childhood onset, often pure. (awuah2024hereditaryspasticparaplegia pages 1-2) - SPG11 (AR): one review estimates ~18% globally, with noted geographic clustering. (awuah2024hereditaryspasticparaplegia pages 1-2) - SPG7 (AR): frequent in complex phenotypes including movement disorders. (azeem2024investigatingthegenetic pages 1-2)

A compact gene–phenotype–mechanism map based on retrieved evidence is provided below.

Subtype (SPG#/Gene) Inheritance (AD/AR/X/mt) Typical phenotype (pure vs complicated; onset) Mechanistic theme Notes/statistics Key citations
HSP disease group AD, AR, X-linked, mitochondrial Pure forms: progressive lower-limb spasticity/weakness, urinary symptoms, mild dorsal column involvement; complicated forms add ataxia, neuropathy, cognitive impairment, seizures, optic atrophy, extrapyramidal signs; onset ranges from infancy to adulthood Convergent pathways include axonal transport defects, ER membrane shaping/trafficking, autophagy/lysosome and AP-4 trafficking defects, mitochondrial dysfunction, abnormal myelination, endosomal dysfunction, oxidative stress, and lipid metabolism abnormalities >80 loci/genes reported; another review notes >90 genes/loci; prevalence estimates in recent reviews span 2–6/100,000 and 3–10/100,000 (awuah2024hereditaryspasticparaplegia pages 1-2, cipriano2025fluidbiomarkersin pages 1-2, maccora2024nonpharmacologicaltreatmentof pages 1-2, faccioli2023gaitanalysispatterns pages 1-2, awuah2024hereditaryspasticparaplegia media cde30dbb)
SPG4 / SPAST AD Usually pure HSP with slowly progressive lower-limb spasticity/weakness; non-motor features can occur; typical onset from childhood to adulthood Microtubule severing and axonal transport/cytoskeletal maintenance Most prevalent AD-HSP; reported as ~40–45% of familial cases and ~40% of autosomal dominant cases; most common genotype in several cohorts (awuah2024hereditaryspasticparaplegia pages 1-2, cipriano2025fluidbiomarkersin pages 1-2, maccora2024nonpharmacologicaltreatmentof pages 1-2, siow2023outcomemeasuresand pages 1-2, awuah2024hereditaryspasticparaplegia media cde30dbb)
SPG3A / ATL1 AD; rare AR forms reported Usually pure childhood-onset HSP with slow progression and many patients remaining ambulatory; severe very-early-onset complex cases can include axial hypotonia, spastic quadriplegia, dystonia, seizures, and intellectual disability ER membrane shaping/fusion and axonal network organization Second most common AD form; one review estimates ~7% of AD-HSP; 2024 report supports possible autosomal recessive SPG3A in exceptional severe cases (awuah2024hereditaryspasticparaplegia pages 1-2, brozkova2026childrenwithsuspected pages 1-2, awuah2024hereditaryspasticparaplegia media cde30dbb)
SPG11 / SPG11 AR Commonly complicated HSP; childhood/juvenile onset common; may include cognitive dysfunction, peripheral neuropathy, parkinsonism, dystonia, and seizures Autophagy/lysosome and endosomal membrane trafficking Reported as ~18% of HSP globally in one 2024 review; in HSP with movement disorders, SPG11 accounted for 23.8%; compared with SPG7 it was more strongly associated with parkinsonism, dystonia, peripheral neuropathy, and cognitive dysfunction (awuah2024hereditaryspasticparaplegia pages 1-2, azeem2024investigatingthegenetic pages 1-2, awuah2024hereditaryspasticparaplegia media cde30dbb)
SPG7 / SPG7 AR Often complicated HSP with adult onset; can feature ataxia, extraocular movement abnormalities, seizures, and movement disorders Mitochondrial dysfunction In HSP with movement disorders, SPG7 was the most frequent genotype at 31.2%; compared with SPG11 it was more often adult-onset (82.9% vs 8.5%) and more associated with ataxia and extraocular movement disturbance (cipriano2025fluidbiomarkersin pages 1-2, azeem2024investigatingthegenetic pages 1-2, awuah2024hereditaryspasticparaplegia media cde30dbb)
SPG30 / KIF1A AD and AR reported Spectrum ranges from mild adult-onset spastic paraplegia to very severe congenital/early-onset complicated disease with developmental delay, neuropathy, optic atrophy, epilepsy, and progressive motor decline Kinesin-mediated anterograde axonal transport Motor-domain missense variants are linked to more severe early phenotypes; adult-onset spastic paraplegia can be less severe; KIF1A-associated disease overlaps HSP and broader KAND spectrum (awuah2024hereditaryspasticparaplegia pages 1-2)
AP-4 deficiency HSPs (e.g., SPG47 / AP4B1; SPG50 / AP4M1) AR Typically early-onset complicated HSP/neurodevelopmental disorder with severe motor impairment AP-4 complex-dependent vesicle trafficking, autophagy/lysosome pathway Emerging gene-replacement trials are active for AP4B1-related SPG47 and AP4M1-related SPG50, supporting AP-4 trafficking as a translational target (schierbaum2025thespasticparaplegia–centers pages 5-5, NCT06692712 chunk 1, NCT06948019 chunk 2)
DDHD2 / SPG54 AR Complicated HSP with intellectual disability, speech/gait impairment, hypertonia, and inability to walk in severe cases Lipid metabolism 2024 family study identified homozygous nonsense variant c.985C>T (p.Arg329Ter) predicted to cause loss of function/nonsense-mediated decay (shafique2024identificationandanalyses pages 1-2)
AP4B1 / SPG47 AR Complicated HSP with developmental and motor impairment AP-4 trafficking, autophagy/lysosome pathway 2024 family study identified homozygous frameshift c.965-967delACTinsC p.(Tyr322SerfsTer14); current gene-therapy program BFB-101 targets AP4B1 deficiency (shafique2024identificationandanalyses pages 1-2, NCT06948019 chunk 2)
SPG5 / CYP7B1-associated HSP AR HSP with biochemical signature; can be pure or complicated Lipid/cholesterol metabolism SPG5 is the clearest subtype with disease-specific fluid biomarker evidence: elevated oxysterols; an interventional trial tested evolocumab with change in 27-hydroxycholesterol as primary outcome (cipriano2025fluidbiomarkersin pages 1-2, awuah2024hereditaryspasticparaplegia pages 20-20, NCT04101643 chunk 1)

Table: This table summarizes the principal hereditary spastic paraplegia subtypes highlighted in the retrieved evidence, linking inheritance and phenotype with convergent pathogenic mechanisms. It is useful as a compact map of which genes dominate the current HSP landscape and which pathways are most relevant for diagnosis and therapeutic development.

2.2 Risk factors

  • Genetic: causal pathogenic variants across many genes; risk is strongly determined by family history and inheritance mode. (maccora2024nonpharmacologicaltreatmentof pages 1-2)
  • Consanguinity: enrichment for AR forms is evident in family-based studies; in a Pakistani cohort, identified pathogenic variants segregated as autosomal recessive in 5/8 families. (azeem2024investigatingthegenetic pages 1-2)

2.3 Protective factors / gene–environment interactions

No protective variants or robust gene–environment protective factors were retrieved in the current corpus. No specific gene–environment interaction evidence was retrieved.

3. Phenotypes (with HPO suggestions)

3.1 Core phenotype spectrum

Pure HSP (typical features): - Progressive lower-limb spasticity and weakness (upper motor neuron syndrome) (HP:0001257 Spasticity; HP:0002061 Gait disturbance; HP:0002360 Hyperreflexia) - Bladder dysfunction/urinary urgency can occur (HP:0000010 Urinary incontinence; HP:0000020 Urinary urgency) (maccora2024nonpharmacologicaltreatmentof pages 1-2)

Complicated/complex HSP (additional features; variable by genotype): - Ataxia (HP:0001251), peripheral neuropathy (HP:0009830), cognitive dysfunction (HP:0100543), epilepsy (HP:0001250), dystonia (HP:0001332), parkinsonism (HP:0001300), optic atrophy (HP:0000648), etc. (cipriano2025fluidbiomarkersin pages 1-2, faccioli2023gaitanalysispatterns pages 1-2)

A large individual participant data meta-analysis focusing on movement disorders in HSP (n=1413) found systematic genotype–phenotype differences: SPG7 and SPG11 were prominent in the HSP-with-movement-disorder subgroup. (fereshtehnejad2023movementdisordersin pages 4-5)

3.2 Onset, severity, progression

  • Onset can occur at any age (childhood to adulthood), and can mimic other conditions (e.g., cerebral palsy-like presentations in unusual early-onset complex cases). (awuah2024hereditaryspasticparaplegia pages 1-2, brozkova2026childrenwithsuspected pages 1-2)
  • In a Pakistani family study, onset among affected individuals ranged 1–14 years (mean 6.23, SD 3.96). (azeem2024investigatingthegenetic pages 1-2)

3.3 Quality of life and disability impact

HSP is commonly characterized as slowly progressive and not life-shortening, but with major long-term disability burden and quality-of-life impairment. (awuah2024hereditaryspasticparaplegia pages 1-2)

In a real-world Austrian cohort (n=126), functional dependence was substantial: 17.5% were wheelchair bound, and ~28.6% were unable to work (with significantly higher work disability in complicated HSP than pure HSP). (amprosi2026naturalhistoryin pages 2-4, amprosi2026naturalhistoryin pages 10-11)

4. Genetic / molecular information

4.1 Variant classes and molecular consequences

Across HSP subtypes, disease-causing variants include: - Missense and loss-of-function (LoF) variants (nonsense/frameshift/splice), and copy number variants (CNVs). (jang2026geneticlandscapeof pages 1-6, shafique2024identificationandanalyses pages 1-2)

Examples (primary literature, 2024): - SPG11 homozygous multi-exon deletion: NC000015.9:g.44894055_449028del. (shafique2024identificationandanalyses pages 1-2) - DDHD2 nonsense: c.985C>T (p.Arg329Ter). (shafique2024identificationandanalyses pages 1-2) - AP4B1 frameshift indel: c.965-967delACTinsC; p.(Tyr322SerfsTer14). (shafique2024identificationandanalyses pages 1-2)

4.2 Modifier genes / epigenetics / chromosomal abnormalities

No specific modifier-gene or epigenetic mechanism evidence was retrieved in the current corpus. Large chromosomal abnormalities were not retrieved, but subtype-relevant CNVs (gene-level) are documented (e.g., SPAST CNVs; SPG11 deletion). (jang2026geneticlandscapeof pages 1-6, shafique2024identificationandanalyses pages 1-2)

5. Environmental information

HSP is fundamentally Mendelian; no consistent environmental toxin/lifestyle/infectious triggers were retrieved as causal or modifying factors in the current corpus.

6. Mechanism / pathophysiology

6.1 Current mechanistic synthesis

Convergent mechanisms proposed in recent reviews include: - Mitochondrial dysfunction (energy failure, axonal vulnerability) (awuah2024hereditaryspasticparaplegia pages 1-2) - ER membrane remodeling and trafficking defects (e.g., ER shaping proteins; ATL1-associated mechanisms) (awuah2024hereditaryspasticparaplegia pages 1-2, awuah2024hereditaryspasticparaplegia media cde30dbb) - Autophagy/lysosomal and endosomal trafficking impairment (including AP-4 complex trafficking in early-onset complicated HSPs) (awuah2024hereditaryspasticparaplegia pages 1-2, schierbaum2025thespasticparaplegia–centers pages 5-5) - Altered lipid metabolism (including SPG5 oxysterol elevations as a disease-linked biochemical signature) (cipriano2025fluidbiomarkersin pages 1-2) - Abnormal myelination and oxidative stress pathways (awuah2024hereditaryspasticparaplegia pages 1-2)

6.2 Causal chain (generalized)

Pathogenic variant (gene-specific) → altered protein function in a convergent pathway (e.g., axonal transport / ER dynamics / mitochondrial function / autophagy / lipid homeostasis) → length-dependent corticospinal axon degeneration (“dying-back”) → progressive spastic paraparesis with possible multi-system neurologic involvement in complicated forms. (awuah2024hereditaryspasticparaplegia pages 1-2, vivarelli2025wingsofdiscovery pages 1-3)

6.3 Suggested ontology terms (mechanisms)

  • GO biological processes (examples): axon transport; autophagy; ER organization; mitochondrial organization; lipid metabolic process; endosome transport.
  • GO cellular components (examples): corticospinal neuron axon; endoplasmic reticulum; mitochondrion; endosome; lysosome; microtubule.

(These are ontology suggestions; specific GO IDs were not retrieved from primary sources in the current corpus.)

7. Anatomical structures affected (with ontology suggestions)

7.1 Organ/system level

  • Primary system: nervous system, especially the corticospinal tracts. (awuah2024hereditaryspasticparaplegia pages 1-2)

UBERON suggestions: corticospinal tract; spinal cord; motor cortex.

7.2 Tissue/cell types

  • Vulnerable populations include upper motor neurons / corticospinal projection neurons.

Cell Ontology (CL) suggestions: cortical pyramidal neuron; upper motor neuron; oligodendrocyte (myelination-related subtypes).

(These are suggestions; specific CL/UBERON IDs were not retrieved in the current corpus.)

8. Temporal development (natural history)

8.1 Onset patterns

HSP can present from infancy to adulthood; pure AD forms often show slow progression, whereas many AR forms are earlier-onset and more complex. (awuah2024hereditaryspasticparaplegia pages 1-2, maccora2024nonpharmacologicaltreatmentof pages 1-2, brozkova2026childrenwithsuspected pages 1-2)

8.2 Quantitative progression (SPRS)

A prospective Austrian cohort study (up to 5-year follow-up) quantified progression using the Spastic Paraplegia Rating Scale (SPRS): - Mean baseline SPRS 18.2 (SD 10.5) - Overall annual progression ~0.9 SPRS points/year - Faster progression in complicated vs pure HSP: 1.3 vs 0.6 SPRS points/year (p<0.001). (amprosi2026naturalhistoryin pages 1-2, amprosi2026naturalhistoryin pages 4-5)

These data support the common expert view that HSP progresses slowly, creating challenges for interventional trial endpoints and motivating biomarker and digital outcome development. (siow2023outcomemeasuresand pages 1-2, cipriano2025fluidbiomarkersin pages 1-2)

9. Inheritance and population

9.1 Epidemiology (prevalence/incidence)

Recent sources provide variable epidemiologic estimates (reflecting ascertainment, genetic testing availability, and region): - A 2023 systematic review reports European prevalence 3–10 per 100,000 and incidence estimates 1.27–9.6 per 100,000 (as reported in included literature). (faccioli2023gaitanalysispatterns pages 1-2) - A 2025 biomarker review reports prevalence often 2–6 per 100,000 (range 0.1–9.6 per 100,000) and notes registry prevalence increases over time (England/N. Ireland: 2.83/100,000 in 2000 to 6.27/100,000 in 2021). (cipriano2025fluidbiomarkersin pages 1-2)

9.2 Mode of inheritance distribution

A systematic review notes that inheritance patterns span AD/AR/X-linked/mitochondrial; in European/North American cohorts, AD is frequently highlighted and 13–40% may be sporadic. (maccora2024nonpharmacologicaltreatmentof pages 1-2)

9.3 Population genetics and founder effects

In Pakistani families, recurrent variants in FA2H and SPG11 were observed and interpreted as suggesting a possible founder effect. (azeem2024investigatingthegenetic pages 1-2)

10. Diagnostics

10.1 Clinical diagnosis and differential considerations

HSP is clinically anchored by a progressive, predominantly UMN lower-limb syndrome; complicated forms require systematic evaluation for additional neurologic features and for treatable mimics. (faccioli2023gaitanalysispatterns pages 1-2)

10.2 Genetic testing and diagnostic yield (recent data)

Key implementation point: CNV detection and broad gene coverage materially affect diagnostic yield.

  • Targeted panel vs Sanger (large cohort): In a Korean series of 657 suspected HSP patients, overall PV/LPV detection was 18%; yield was 25% using a 54-gene targeted NGS panel versus 16% with Sanger sequencing. Importantly, 5% of SPAST mutations were CNVs, supporting routine CNV analysis. (jang2026geneticlandscapeof pages 1-6, jang2026geneticlandscapeof pages 11-16)
  • WES in resource-limited settings (family study): In Pakistani families, WES plus segregation analysis identified pathogenic variants in 5/8 families (62.5%), all consistent with AR inheritance. (azeem2024investigatingthegenetic pages 1-2)
  • CNV calling from exomes: A 2024 family study explicitly used ExomeDepth CNV calling and identified a homozygous multi-exon SPG11 deletion (example of CNVs as causal events detectable from exome data). (shafique2024identificationandanalyses pages 1-2)

10.3 Biomarkers and imaging (state of evidence)

Fluid biomarkers: A 2025 integrative review concludes that no universal biomarker spans HSP heterogeneity, but highlights downstream biomarkers reflecting shared neurodegeneration—NfL, brain-derived tau, GFAP, and soluble TREM2—and notes that SPG5 oxysterols are among the clearest disease-linked biochemical candidates. (cipriano2025fluidbiomarkersin pages 1-2)

Imaging: In the Austrian cohort, MRI was available for 76% and cerebral/cerebellar atrophy were each observed in >40% (cohort includes complicated forms); thin corpus callosum was reported in 13%. (amprosi2026naturalhistoryin pages 11-13)

11. Outcome / prognosis

11.1 Survival

A 2024 review states HSP “does not reduce a person’s lifespan” but “significantly impairs their quality of life as they age.” (awuah2024hereditaryspasticparaplegia pages 1-2)

11.2 Morbidity and disability

Natural history data demonstrate gradual but measurable progression: - Annual SPRS progression ~0.9 points/year overall, with complicated forms progressing faster. (amprosi2026naturalhistoryin pages 1-2, amprosi2026naturalhistoryin pages 4-5) - Substantial rates of assistive-device use and wheelchair dependence in real-world cohorts. (amprosi2026naturalhistoryin pages 2-4)

12. Treatment

12.1 Current standard-of-care (symptomatic, multidisciplinary)

There is broad expert consensus across recent reviews that no disease-modifying therapy currently halts or reverses HSP progression. (awuah2024hereditaryspasticparaplegia pages 1-2, maccora2024nonpharmacologicaltreatmentof pages 1-2, siow2023outcomemeasuresand pages 1-2)

A systematic review of non-pharmacological treatment emphasizes multidisciplinary symptomatic management, and lists commonly used symptom-directed medications including baclofen, tizanidine, oxybutynin, 4-aminopyridine, botulinum toxin A, and intrathecal baclofen in refractory cases. (maccora2024nonpharmacologicaltreatmentof pages 1-2)

MAXO suggestions (management actions): physical therapy; gait training; chemodenervation (botulinum toxin injection); intrathecal drug delivery (baclofen); orthotic management; genetic counseling.

12.2 Rehabilitation and real-world implementations (2023–2024 evidence)

Rehabilitation modalities studied include: electrostimulation/FES, hydrotherapy, robot-assisted gait training, balance rehabilitation, and neuromodulation. (ludovico2023thetherapeuticeffects pages 1-2, maccora2024nonpharmacologicaltreatmentof pages 2-4)

  • A 2023 narrative review concluded: “Electrostimulation, magnetotherapy, hydrotherapy, PT, robot-assisted gait training, and balance rehabilitation have the potential to increase lower extremity strength and decrease spasticity in HSP patients.” (ludovico2023thetherapeuticeffects pages 1-2)
  • A 2024 systematic review of non-pharmacologic interventions included 13 articles (117 patients; only 37 genetically confirmed) and found heterogeneous outcomes and generally low evidence quality, with no PROMs used in included trials. (maccora2024nonpharmacologicaltreatmentof pages 2-4, maccora2024nonpharmacologicaltreatmentof pages 6-7)
  • A 2023 systematic review/meta-analysis describes HSP gait signatures (e.g., knee hyperextension, reduced ROM) and reports that interventions reducing spasticity can sometimes “unmask” weakness; evidence for intrathecal baclofen and intensive active PT/FES was described as weak but potentially beneficial short-term for gait velocity. (faccioli2023gaitanalysispatterns pages 1-2)

12.3 Emerging/interventional trials (ClinicalTrials.gov)

Gene therapy / gene replacement (AP-4 deficiency spectrum): - SPG50 (AP4M1): intrathecal MELPIDA (AAV9/AP4M1), Phase 3, recruiting; NCT06692712 (sponsor: Elpida Therapeutics). Primary endpoint includes GMFM-88 milestone-based measures; includes matched concurrent controls. (NCT06692712 chunk 1) - SPG47 (AP4B1): BFB-101 (AAV9/AP4B1), early pediatric gene transfer trial; NCT06948019 (sponsor: BlackfinBio Ltd; site includes Boston Children’s Hospital). (NCT06948019 chunk 2)

Metabolic/biochemical targeting: - SPG5: evolocumab (PCSK9 inhibitor) Phase 1/2 trial; NCT04101643; primary outcome includes change in 27-hydroxycholesterol. (NCT04101643 chunk 1)

(Other HSP trials exist in the retrieved ClinicalTrials.gov set but were not fully extracted into evidence snippets in this run.)

13. Prevention

Primary prevention of HSP (in the public-health sense) is generally not applicable for Mendelian forms; prevention focuses on genetic counseling and reproductive options.

Secondary/tertiary prevention: early recognition of complicated features, fall prevention, management of bladder symptoms, and structured rehabilitation to mitigate complications and preserve mobility. Evidence for urinary dysfunction burden and under-treatment is noted in cohort data (38% urinary dysfunction; 14% treated). (amprosi2026naturalhistoryin pages 11-13)

14. Other species / natural disease

No naturally occurring non-human HSP disease epidemiology (e.g., OMIA) was retrieved in the current corpus.

15. Model organisms

15.1 Drosophila and translational model pipelines

A 2025 review highlights Drosophila melanogaster as a powerful HSP model platform because of genetic tractability and conserved biology; it emphasizes “advanced genetic tools, including RNA interference, CRISPR/Cas9, and the GAL4/UAS system” and “high-throughput drug screening platforms” to test therapeutic candidates. (vivarelli2025wingsofdiscovery pages 1-3)

Mechanistic and translational uses include: - Modeling core HSP genes (e.g., SPAST/spastin, ATL1/atlastin, SPG7) and measuring locomotion/NMJ phenotypes, mitochondrial/ER defects, and neurodegeneration. (vivarelli2025wingsofdiscovery pages 5-7, vivarelli2025wingsofdiscovery pages 17-19) - Use of patient-specific “avatars”: “Large-scale chemical libraries, including FDA-approved drugs, can be screened in patient-specific fly models to identify compounds that rescue disease phenotypes.” (vivarelli2025wingsofdiscovery pages 22-23)

The same review frames a complementary pipeline combining fly models for rapid genetics and screening, murine models for validation in a fully myelinated CNS, and human iPSC-based cellular models for patient-specific mechanisms and higher-throughput testing. (vivarelli2025wingsofdiscovery pages 19-20)

Expert synthesis (2023–2024 emphasis)

  1. Key concept: HSP is best treated as a syndrome-level diagnosis with mandatory escalation to gene-informed classification, because genotype predicts complexity and can enable subtype-targeted trials (e.g., AP-4 deficiency gene therapy; SPG5 biochemical targets). (awuah2024hereditaryspasticparaplegia pages 1-2, NCT06692712 chunk 1, NCT04101643 chunk 1)
  2. Trial-readiness challenge: Slow progression (e.g., ~0.9 SPRS points/year overall) necessitates standardized clinical scales, digital gait endpoints, and fluid biomarkers for feasible study designs. (amprosi2026naturalhistoryin pages 4-5, siow2023outcomemeasuresand pages 1-2, cipriano2025fluidbiomarkersin pages 1-2)
  3. Implementation priority: Genetic workflows should include CNV detection (illustrated by SPAST CNVs and SPG11 deletions) and should be designed as tiered testing (panel → WES/WGS) as unresolved cases remain common. (jang2026geneticlandscapeof pages 1-6, shafique2024identificationandanalyses pages 1-2)

Direct abstract-supported statements (quotes)

  • “Hereditary spastic paraplegia is a genetically heterogeneous neurodegenerative disorder characterised primarily by muscle stiffness in the lower limbs.” (SAGE Open Medicine review, 2024) (awuah2024hereditaryspasticparaplegia pages 1-2)
  • “Hereditary spastic paraplegia (HSP) is a rare genetic disorder associated with mutations in > 80 loci designated SPG (SPastic parapleGia).” (Systematic review/IPD meta-analysis, 2023) (fereshtehnejad2023movementdisordersin pages 4-5)
  • “Electrostimulation, magnetotherapy, hydrotherapy, PT, robot-assisted gait training, and balance rehabilitation have the potential to increase lower extremity strength and decrease spasticity in HSP patients.” (Narrative review, 2023) (ludovico2023thetherapeuticeffects pages 1-2)

Data gaps and limitations of this run

  • Ontology identifiers (OMIM/Orphanet/ICD/MeSH/MONDO codes) were not directly retrieved from the current corpus, and are therefore explicitly marked “not retrieved” to avoid fabrication. (artifact-00)
  • Several high-value 2023–2024 mechanistic and genotype-distribution primary studies exist but were not all accessible in full text in this run; the report therefore emphasizes retrieved reviews and cohorts with explicit quantitative data.

References

  1. (awuah2024hereditaryspasticparaplegia media cde30dbb): Wireko Andrew Awuah, Joecelyn Kirani Tan, Anastasiia D Shkodina, Tomas Ferreira, Favour Tope Adebusoye, Adele Mazzoleni, Jack Wellington, Lian David, Ellie Chilcott, Helen Huang, Toufik Abdul-Rahman, Vallabh Shet, Oday Atallah, Jacob Kalmanovich, Riaz Jiffry, Divine Elizabeth Madhu, Kateryna Sikora, Oleksii Kmyta, and Mykhailo Yu Delva. Hereditary spastic paraplegia: novel insights into the pathogenesis and management. SAGE Open Medicine, Dec 2024. URL: https://doi.org/10.1177/20503121231221941, doi:10.1177/20503121231221941. This article has 30 citations.

  2. (awuah2024hereditaryspasticparaplegia pages 1-2): Wireko Andrew Awuah, Joecelyn Kirani Tan, Anastasiia D Shkodina, Tomas Ferreira, Favour Tope Adebusoye, Adele Mazzoleni, Jack Wellington, Lian David, Ellie Chilcott, Helen Huang, Toufik Abdul-Rahman, Vallabh Shet, Oday Atallah, Jacob Kalmanovich, Riaz Jiffry, Divine Elizabeth Madhu, Kateryna Sikora, Oleksii Kmyta, and Mykhailo Yu Delva. Hereditary spastic paraplegia: novel insights into the pathogenesis and management. SAGE Open Medicine, Dec 2024. URL: https://doi.org/10.1177/20503121231221941, doi:10.1177/20503121231221941. This article has 30 citations.

  3. (cipriano2025fluidbiomarkersin pages 1-2): Lorenzo Cipriano, Nunzio Setola, Melissa Barghigiani, and Filippo Maria Santorelli. Fluid biomarkers in hereditary spastic paraplegia: a narrative review and integrative framework for complex neurodegenerative mechanisms. Genes, 16:1189, Oct 2025. URL: https://doi.org/10.3390/genes16101189, doi:10.3390/genes16101189. This article has 1 citations.

  4. (maccora2024nonpharmacologicaltreatmentof pages 1-2): Simona Maccora, Angelo Torrente, Vincenzo Di Stefano, Antonino Lupica, Salvatore Iacono, Laura Pilati, Antonia Pignolo, and Filippo Brighina. Non-pharmacological treatment of hereditary spastic paraplegia: a systematic review. Neurological Sciences, 45:963-976, Nov 2024. URL: https://doi.org/10.1007/s10072-023-07200-1, doi:10.1007/s10072-023-07200-1. This article has 10 citations and is from a peer-reviewed journal.

  5. (faccioli2023gaitanalysispatterns pages 1-2): Silvia Faccioli, Angela Cavalagli, Nicola Falocci, Giulia Mangano, Irene Sanfilippo, and Silvia Sassi. Gait analysis patterns and rehabilitative interventions to improve gait in persons with hereditary spastic paraplegia: a systematic review and meta-analysis. Frontiers in Neurology, Sep 2023. URL: https://doi.org/10.3389/fneur.2023.1256392, doi:10.3389/fneur.2023.1256392. This article has 33 citations and is from a peer-reviewed journal.

  6. (brozkova2026childrenwithsuspected pages 1-2): Dana Safka Brozkova, Jaroslava Paulasova Schwabova, Emilie Vyhnalkova, Petra Lassuthova, Alena Musilova, Ludmila Novotna, Jana Vasova, and Anna Uhrova Meszarosova. Children with suspected hereditary spastic paraplegia clearly benefit from whole exome analysis. Human Genomics, Feb 2026. URL: https://doi.org/10.1186/s40246-026-00935-w, doi:10.1186/s40246-026-00935-w. This article has 0 citations and is from a peer-reviewed journal.

  7. (azeem2024investigatingthegenetic pages 1-2): Arfa Azeem, Asif Naveed Ahmed, Niamat Khan, Nikol Voutsina, Irfan Ullah, Nishanka Ubeyratna, Muhammad Yasin, Emma L. Baple, Andrew H. Crosby, Lettie E. Rawlins, and Shamim Saleha. Investigating the genetic basis of hereditary spastic paraplegia and cerebellar ataxia in pakistani families. BMC Neurology, Sep 2024. URL: https://doi.org/10.1186/s12883-024-03855-1, doi:10.1186/s12883-024-03855-1. This article has 4 citations and is from a peer-reviewed journal.

  8. (siow2023outcomemeasuresand pages 1-2): Sue-Faye Siow, Dennis Yeow, Laura I. Rudaks, Fangzhi Jia, Gautam Wali, Carolyn M. Sue, and Kishore R. Kumar. Outcome measures and biomarkers for clinical trials in hereditary spastic paraplegia: a scoping review. Genes, 14:1756, Sep 2023. URL: https://doi.org/10.3390/genes14091756, doi:10.3390/genes14091756. This article has 17 citations.

  9. (NCT04101643 chunk 1): Wan-Jin Chen. PCSK9 Inhibitor Treatment for Patients With SPG5. First Affiliated Hospital of Fujian Medical University. 2019. ClinicalTrials.gov Identifier: NCT04101643

  10. (schierbaum2025thespasticparaplegia–centers pages 5-5): Luca Schierbaum, Vicente Quiroz, Kathryn Yang, Joshua Rong, Nicole Battaglia, Umar Zubair, Michelle Christie, Marie Davis, Daniel Calame, Matt C. Danzi, Richard S. Finkel, Joshua Burns, Donald L. Gilbert, Dararat Mingbunjerdsuk, Greg Pruitt, Norma Pruitt, John Cobb, Reza Sadjadi, Christopher R. Cashman, Craig Blackstone, John K. Fink, Michael E. Shy, Stephan Zuchner, and Darius Ebrahimi-Fakhari. The spastic paraplegia–centers of excellence research network (sp-cern). Neurology Genetics, Apr 2025. URL: https://doi.org/10.1212/nxg.0000000000200249, doi:10.1212/nxg.0000000000200249. This article has 6 citations.

  11. (NCT06692712 chunk 1): Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.. Elpida Therapeutics SPC. 2026. ClinicalTrials.gov Identifier: NCT06692712

  12. (NCT06948019 chunk 2): Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47). BlackfinBio Ltd. 2025. ClinicalTrials.gov Identifier: NCT06948019

  13. (shafique2024identificationandanalyses pages 1-2): Anum Shafique, Ayesha Nadeem, Faiza Aslam, Humera Manzoor, Muhammad Noman, Elizabeth Wohler, P. Dane Witmer, Nara Sobreira, and Sadaf Naz. Identification and analyses of exonic and copy number variants in spastic paraplegia. Scientific Reports, Jun 2024. URL: https://doi.org/10.1038/s41598-024-64922-8, doi:10.1038/s41598-024-64922-8. This article has 0 citations and is from a peer-reviewed journal.

  14. (awuah2024hereditaryspasticparaplegia pages 20-20): Wireko Andrew Awuah, Joecelyn Kirani Tan, Anastasiia D Shkodina, Tomas Ferreira, Favour Tope Adebusoye, Adele Mazzoleni, Jack Wellington, Lian David, Ellie Chilcott, Helen Huang, Toufik Abdul-Rahman, Vallabh Shet, Oday Atallah, Jacob Kalmanovich, Riaz Jiffry, Divine Elizabeth Madhu, Kateryna Sikora, Oleksii Kmyta, and Mykhailo Yu Delva. Hereditary spastic paraplegia: novel insights into the pathogenesis and management. SAGE Open Medicine, Dec 2024. URL: https://doi.org/10.1177/20503121231221941, doi:10.1177/20503121231221941. This article has 30 citations.

  15. (fereshtehnejad2023movementdisordersin pages 4-5): Seyed-Mohammad Fereshtehnejad, Philip A. Saleh, Lais M. Oliveira, Neha Patel, Suvorit Bhowmick, Gerard Saranza, and Lorraine V. Kalia. Movement disorders in hereditary spastic paraplegia (hsp): a systematic review and individual participant data meta-analysis. Neurological Sciences, 44:947-959, Nov 2023. URL: https://doi.org/10.1007/s10072-022-06516-8, doi:10.1007/s10072-022-06516-8. This article has 18 citations and is from a peer-reviewed journal.

  16. (amprosi2026naturalhistoryin pages 2-4): Matthias Amprosi, Elisabetta Indelicato, Andreas Eigentler, Daniel Boesch, Josef Fritz, Wolfgang Nachbauer, and Sylvia Boesch. Natural history in hereditary spastic paraplegias: real-world data from an austrian cohort. Journal of Neurology, Jan 2026. URL: https://doi.org/10.1007/s00415-025-13606-y, doi:10.1007/s00415-025-13606-y. This article has 0 citations and is from a domain leading peer-reviewed journal.

  17. (amprosi2026naturalhistoryin pages 10-11): Matthias Amprosi, Elisabetta Indelicato, Andreas Eigentler, Daniel Boesch, Josef Fritz, Wolfgang Nachbauer, and Sylvia Boesch. Natural history in hereditary spastic paraplegias: real-world data from an austrian cohort. Journal of Neurology, Jan 2026. URL: https://doi.org/10.1007/s00415-025-13606-y, doi:10.1007/s00415-025-13606-y. This article has 0 citations and is from a domain leading peer-reviewed journal.

  18. (jang2026geneticlandscapeof pages 1-6): Mi-Ae Jang, Ja-Hyun Jang, Byoung Joon Kim, and Duk Hyun Sung. Genetic landscape of hereditary spastic paraplegias in the korean population. Scientific Reports, May 2026. URL: https://doi.org/10.1038/s41598-026-53107-0, doi:10.1038/s41598-026-53107-0. This article has 0 citations and is from a peer-reviewed journal.

  19. (vivarelli2025wingsofdiscovery pages 1-3): Rachele Vivarelli, Chiara Vantaggiato, Maria Teresa Bassi, Filippo Maria Santorelli, and Maria Marchese. Wings of discovery: using drosophila to decode hereditary spastic paraplegia and ataxias. Cells, 14:1466, Sep 2025. URL: https://doi.org/10.3390/cells14181466, doi:10.3390/cells14181466. This article has 1 citations.

  20. (amprosi2026naturalhistoryin pages 1-2): Matthias Amprosi, Elisabetta Indelicato, Andreas Eigentler, Daniel Boesch, Josef Fritz, Wolfgang Nachbauer, and Sylvia Boesch. Natural history in hereditary spastic paraplegias: real-world data from an austrian cohort. Journal of Neurology, Jan 2026. URL: https://doi.org/10.1007/s00415-025-13606-y, doi:10.1007/s00415-025-13606-y. This article has 0 citations and is from a domain leading peer-reviewed journal.

  21. (amprosi2026naturalhistoryin pages 4-5): Matthias Amprosi, Elisabetta Indelicato, Andreas Eigentler, Daniel Boesch, Josef Fritz, Wolfgang Nachbauer, and Sylvia Boesch. Natural history in hereditary spastic paraplegias: real-world data from an austrian cohort. Journal of Neurology, Jan 2026. URL: https://doi.org/10.1007/s00415-025-13606-y, doi:10.1007/s00415-025-13606-y. This article has 0 citations and is from a domain leading peer-reviewed journal.

  22. (jang2026geneticlandscapeof pages 11-16): Mi-Ae Jang, Ja-Hyun Jang, Byoung Joon Kim, and Duk Hyun Sung. Genetic landscape of hereditary spastic paraplegias in the korean population. Scientific Reports, May 2026. URL: https://doi.org/10.1038/s41598-026-53107-0, doi:10.1038/s41598-026-53107-0. This article has 0 citations and is from a peer-reviewed journal.

  23. (amprosi2026naturalhistoryin pages 11-13): Matthias Amprosi, Elisabetta Indelicato, Andreas Eigentler, Daniel Boesch, Josef Fritz, Wolfgang Nachbauer, and Sylvia Boesch. Natural history in hereditary spastic paraplegias: real-world data from an austrian cohort. Journal of Neurology, Jan 2026. URL: https://doi.org/10.1007/s00415-025-13606-y, doi:10.1007/s00415-025-13606-y. This article has 0 citations and is from a domain leading peer-reviewed journal.

  24. (ludovico2023thetherapeuticeffects pages 1-2): Armando Di Ludovico, Francesca Ciarelli, Saverio La Bella, Giovanna Scorrano, Francesco Chiarelli, and Giovanni Farello. The therapeutic effects of physical treatment for patients with hereditary spastic paraplegia: a narrative review. Frontiers in Neurology, Nov 2023. URL: https://doi.org/10.3389/fneur.2023.1292527, doi:10.3389/fneur.2023.1292527. This article has 13 citations and is from a peer-reviewed journal.

  25. (maccora2024nonpharmacologicaltreatmentof pages 2-4): Simona Maccora, Angelo Torrente, Vincenzo Di Stefano, Antonino Lupica, Salvatore Iacono, Laura Pilati, Antonia Pignolo, and Filippo Brighina. Non-pharmacological treatment of hereditary spastic paraplegia: a systematic review. Neurological Sciences, 45:963-976, Nov 2024. URL: https://doi.org/10.1007/s10072-023-07200-1, doi:10.1007/s10072-023-07200-1. This article has 10 citations and is from a peer-reviewed journal.

  26. (maccora2024nonpharmacologicaltreatmentof pages 6-7): Simona Maccora, Angelo Torrente, Vincenzo Di Stefano, Antonino Lupica, Salvatore Iacono, Laura Pilati, Antonia Pignolo, and Filippo Brighina. Non-pharmacological treatment of hereditary spastic paraplegia: a systematic review. Neurological Sciences, 45:963-976, Nov 2024. URL: https://doi.org/10.1007/s10072-023-07200-1, doi:10.1007/s10072-023-07200-1. This article has 10 citations and is from a peer-reviewed journal.

  27. (vivarelli2025wingsofdiscovery pages 5-7): Rachele Vivarelli, Chiara Vantaggiato, Maria Teresa Bassi, Filippo Maria Santorelli, and Maria Marchese. Wings of discovery: using drosophila to decode hereditary spastic paraplegia and ataxias. Cells, 14:1466, Sep 2025. URL: https://doi.org/10.3390/cells14181466, doi:10.3390/cells14181466. This article has 1 citations.

  28. (vivarelli2025wingsofdiscovery pages 17-19): Rachele Vivarelli, Chiara Vantaggiato, Maria Teresa Bassi, Filippo Maria Santorelli, and Maria Marchese. Wings of discovery: using drosophila to decode hereditary spastic paraplegia and ataxias. Cells, 14:1466, Sep 2025. URL: https://doi.org/10.3390/cells14181466, doi:10.3390/cells14181466. This article has 1 citations.

  29. (vivarelli2025wingsofdiscovery pages 22-23): Rachele Vivarelli, Chiara Vantaggiato, Maria Teresa Bassi, Filippo Maria Santorelli, and Maria Marchese. Wings of discovery: using drosophila to decode hereditary spastic paraplegia and ataxias. Cells, 14:1466, Sep 2025. URL: https://doi.org/10.3390/cells14181466, doi:10.3390/cells14181466. This article has 1 citations.

  30. (vivarelli2025wingsofdiscovery pages 19-20): Rachele Vivarelli, Chiara Vantaggiato, Maria Teresa Bassi, Filippo Maria Santorelli, and Maria Marchese. Wings of discovery: using drosophila to decode hereditary spastic paraplegia and ataxias. Cells, 14:1466, Sep 2025. URL: https://doi.org/10.3390/cells14181466, doi:10.3390/cells14181466. This article has 1 citations.

Artifacts